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ABSTRACT 
 
Meperidine has been shown to have potent binding affinity for serotonin transporters 
(SERT) (Ki = 41 nM) and be an inhibitor of serotonin reuptake. Based upon these 
pharmacological results meperidine has been identified as a lead compound for the development 
of a novel class of serotonin-selective reuptake inhibitors (SSRIs). 
A variety of potent analogues of meperidine have been synthesized and evaluated in vitro 
as potential ligands for the serotonin transporter. Substitutions have been made on the aryl ring, 
the ester moiety and the piperidine nitrogen of meperidine. Potent analogues of the aryl 
substituted series that included 4-iodophenyl, 2-naphthyl, 3,4-dichlorophenyl and 4-biphenyl 
meperidine derivatives were synthesized and chosen for further optimization of the benzyl ester 
analogues. Benzyl ester analogues included 4-nitro, 4-methoxyl and 3,4-dichloro benzyl 
analogues and exhibited high potency for serotonin transporters and high selectivity over the 
dopamine transporter (DAT) and the norepinephrine transporter (NET). Also the N-demethylated 
analogues improve the binding affinity and selectivity for serotonin transporter. The analogue 4-
(carboxymethoxybenzyl)-4-(4-iodophenyl) piperidine (69f), was found the most potent (Ki=0.6 
nM) and selective ligand for serotonin transporter (DAT/SERT >4500; NET/SERT >4500) for 
the series and has been advanced to in vivo evaluation. 
 
Keywords: meperidine, piperidine, serotonin transporter, SSRIs, antidepressant. 
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INTRODUCTION 
 
Neurotransmitters  
Neurotransmitters are endogenous chemicals released from presynaptic neurons to 
stimulate neighboring neurons, allowing impulses to be passed throughout the nervous system. A 
nerve impulse arriving at the axon terminal of one neuron stimulates release of a 
neurotransmitter, which crosses the synaptic cleft to the adjoining neuron's dendrite. (Figure 1).1  
 
  
                     
 
 
 
 
 
 
 
                                   Figure 1. Neuron cell and neurotransmitters1.  
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  There are many different classifications of neurotransmitters, but most of these neuro-
transmitters are divided into following major groups for research purposes: 
• Amino acids: glutamate,2 aspartate,3 serine,4 γ-aminobutyric acid (GABA),5 glycine.6 
• Monoamines: dopamine (DA),7 serotonin (SE, 5-HT),8 norepinephrine (noradrenaline; 
                                            NE),9 epinephrine (adrenaline),10 histamine,11 melatonin.12 
• Others:  acetylcholine (ACh),13 adenosine,14 anandamide,15 nitric oxide,16 etc. 
All these neurotransmitters are released by specific neurons and showing their different 
effects on central nervous system. The direct effect of a neurotransmitter is to activate one or 
more types of receptors. The effect on the postsynaptic cell depends, therefore, entirely on the 
properties of those receptors. It happens that for some neurotransmitters, the most important 
receptors have excitatory effects: that is, they increase the probability that the target cell will fire 
an action potential. For other neurotransmitters, the most important receptors have inhibitory 
effects. There are, however, other neurotransmitters, such as acetylcholine, for which both 
excitatory and inhibitory receptors exist,17,18 and there are some types of receptors that activate 
complex metabolic pathways in the postsynaptic cell to produce effects that cannot appropriately 
be called either excitatory or inhibitory.  
 
Monoamine Neurotransmitters  
Monoamine neurotransmitters are neurotransmitters that contain one amino group that is 
connected to an aromatic ring by a two-carbon chain (-CH2-CH2-). All monoamines are derived 
from aromatic amino acids like phenylalanine, tyrosine, tryptophan, and the thyroid hormones by 
the action of aromatic amino acid decarboxylase enzymes.19 The most important members in this 
group are dopamine (DA, 1), serotonin (SE, 2), and norepinephrine (NE, 3). Despite their similar 
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structures, they have different roles in neurotransmission and have specific receptor/transporter 
mechanism.  
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As mentioned above, the different concentration levels of these monoamines will enhance 
or weaken the receptor binding activities and so lead to different levels of stimulation. The 
releasing and reuptake actions of these monoamines are illustrated in Figure 2.20  
 
 
Figure 2. Monoamine transporters and reuptake action20 
 
In the synaptic cleft, some the released monoamines are bound to the receptors on 
postsynaptic membranes, which can initiate an action potential. However, the remaining 
concentration of unbound monoamine will be recovered by their transporters and sent back to 
4 
 
presynaptic vesicles waiting the next wave of releasing impulses. In addition some of 
monoamine will be metabolized and degraded by specific enzymes like monoamine oxidases. 
Most Central Nervous System (CNS) medications are working on neurotransmitter 
systems due to their specific drug targeting. For example, Parkinson's disease is at least in part 
related to failure of dopaminergic cells in deep-brain nuclei. Also, Cocaine, for example, blocks 
the reuptake of dopamine back into the presynaptic neuron, leaving the neurotransmitter 
molecules in the synaptic gap longer. A brief comparison of the major drugs targeting these 
neurotransmitter systems is listed as Table 1. 
 
Table 1. Monoamines and their Drug Targeting 
 
 
 
Monoamines Physiological Effect Drug Targeting 
Dopamine  (DA) 
Reward system , Motor 
system, Cognition , etc.  
Cocaine Addiction, Parkinson , 
Alzheimer,  
Serotonin   (SE) 
Mood, Satiety, Body 
temperature, Sleep, etc.  
Depression, Psychotics, Migraine.  
Norepinephrine (NE) 
Reward system, Arousal, 
also hormone, etc.  
Attention-deficit/ hyperactivity 
disorder, depression and 
hypotension  
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One important method to modulate the extracellular (cleft) level of monoamine is by 
blocking the reuptake route by inhibiting the transporter proteins. Monoamine transporters are 
the proteins on the presynaptic membrane that transfer the free monoamines from synaptic cleft 
back to the presynaptic cells. This procedure is also called “reuptake”. Monoamine transporters 
are specific and highly selective. As in Figure 2, the dopamine transporters (DAT) only reuptake 
dopamine and the serotonin transporters (SERT) and norepinephrine transporters (NET) only 
reuptake the corresponding monoamine. Drugs that bind to these transporters either physically 
block of allosterically modulate the transporter protein structure to prevent the re-uptake of the 
corresponding monoamine. This leads to sustained extracellular concentration of the monoamine 
and continued excitation of the monoamineric system. Not until the drug/inhibitor is removed 
from the system, does system return to the “normal” state.  
 
Monoamine Transporters and Their Genes   
Dopamine transporters (DAT), as well as serotonin transporters (SERT) and 
norepinephrine transporters (NET), belong to the same solute carrier family of Na+ or Cl- 
dependent neurotransmitter transporters, and are also known as neurotransmitter sodium 
symporters (NSSs) family 2.A.22, which include serotonin autoreceptors, glycine, γ-
aminobutyric acid (GABA), and other amino acid neurotransmitters. 21 
  In 1990s, express cloning of these transporters was successfully fulfilled from various 
sources including human, monkey, rat, mouse and cow.22-29 The gene for human DAT is 
officially termed the Solute Ligand Carrier Family 6A, Member 3 (SLC6A3), with the number 3 
indicating that it was the third gene in the family of neurotransmitter transporter genes to be 
cloned, after the γ-aminobutyric acid (GABA) and norepinephrine transporters.30 The dopamine 
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transporter gene is located on chromosome 5p15, with a region of over 64 kilobase (kb) long and 
comprising 15 exons encoding a protein of 630 amino acid.31,32 The human serotonin transporter 
(SLC6A4) spans 37.8 kb on chromosome 17q11.2, and is composed of fourteen exons encoding 
a protein of 630 amino acids.33,34 The norepinephrine transporter, with the gene symbol SLC6A2, 
consists of 14 exons spanning 45 kb chromosome 16 locus 16q12.2.31. The human NET is a 617 
amino acid (aa) protein which shows 66% overall identity in amino acid sequence with the 
human DAT and 48% identity with  the human  SERT.34-37 These gene code locations on human 
chromosome are illustrated in Figure 3.  
 
 
Figure 3.Human chromosome with locations of DAT, SERT and NET 
 
Serotonin Transporter: Homology and Structure  
Although the human serotonin transporter gene was sequenced and cloned a decade ago, 
the tertiary structure of serotonin transport protein is still unclear due to limited quantities of 
dissolved membrane proteins for even initial studies. This challenge comes from its nature to 
easy decompose and aggregate.38-40  
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So far the only available structural 3-D models for serotonin transporter are bacterial 
transporter homology such as lactose permease,39 the glycerol-3-phosphate transporter,38 and the 
adenine nucleotide exchanger in mitochondria.41 Among these three bacterial homologies, 
extensive studies of the LacY permease of Escherichia coli and other major facilitator 
superfamily (MFS) carriers were focused. Despite the fact that these proteins share 20% 
similarities with human serotonin transporter, they do not belong to the same family as SERT 
and their topology might therefore be different. Indeed, some important residues for ligand 
binding are missed in LacY- based SERT model.41-43 
Recently, more and more homology studies are focus on the bacterial leucine transporter 
(LeuT) from Aquifex aeolicus, which belongs to the same transport as SERT and shares 20–25% 
identity in primary sequence and 40 to 45% similarity with human neurotransmitter transporters 
with the human neurotransmitter transporters.44,45  
Hydrophobicity analysis of these transporters amino acid sequences revealed the same 
presence of 12 transmembranes (TMs) spanning domains, consisting primarily of α-helical 
structure. The TMs are linked through intracellular and extracellular loops (ILs and ELs), with 
the N- and C-termini facing the cytoplasm.44 (Figure 4). The second extracellular loop (EL2, 
between TM3 and TM4) is characteristic of this transporter family, being the largest connecting 
loops and containing extensive gylcosylation and disulfide bonding.46 Many residues predicted 
by the initial topological predictions to lie in hydrophilic loops were demonstrated to be 
accessible from the appropriate side of the membrane.30,47 These studies extensively utilized 
cysteine scanning mutagenesis of internal and external loops and transmembrane domains. 
Topology Studies generated from the crystal structure of LeuT detected various reactive sites on 
both ELs and ILs, especially on EL3 and EL4.30, 48-50 
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Figure 4.Basic Structure of Monoamine Transporters (illustration only) 
 
Despite the major advance in our understanding provided by the structure of LeuT, many 
aspects of SERT structure remain unresolved. The difference in ion coupling between SERT and 
LeuT must be reflected in differences in the structure of the substrate binding site. In addition, 
there are three regions of SERT where the structure of LeuT provides little or no information. 
The first of these is EL2, which is much longer in SERT than in LeuT. The second is that SERT 
has much longer NH2- and COOH-terminal regions than does LeuT, which contain specific 
domains with potential interaction with the intracellular face of the central region of SERT.51 
 
Mechanism of Serotonin Transporters  
One generalized mechanism for transport is based on the well-known alternate access 
model.52,53 In this model, transporters are believed to function by alternately exposing a substrate 
binding site to the cytoplasmic and extracellular faces of the plasma membrane. The model 
allows solutes to be transported from one side of the membrane to the other, but more 
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importantly, it provides a mechanism for a transmembrane concentration difference of one solute 
to be utilized as a driving force to generate a concentration difference for another solute. The two 
main mechanisms for this process, named symport and antiport by Mitchell et al., couple the 
movement of two solutes moving in the same direction across the membrane or in opposite 
directions, respectively.54 In symport, two (or more) solutes bind to the transporter in one 
conformation, and are later released to the opposite side of the membrane from another 
conformation. In antiport, binding of one solute facilitates conversion of the transporter to the 
form facing the opposite side of the membrane. After dissociation of the first solute, binding of a 
second solute allows the reverse conformational change leading to dissociation of the second 
solute on the side of the membrane where the first solute originated. 
In 2008, A more improved model of mechanism is been proposed, which is based on 
different homology conducted among the families of neurotransmitter sodium symporters [NSS; 
glutamate transporter (GltPh) and leucine transporter (LeuT)], solute sodium symporters [SSS; 
sodium galactose transporter (vSGLT)], and nucleobase cation symporters [NCS1; benzyl-
hydantoin transporter (Mhp1)].43,55-59 Although belonging to three evolutionarily distinct protein 
families with no primary amino acid sequence similarity and different substrate specificities, all 
four transporters share a similar structure and suggest transporter structure consists of two V-
shaped domains (with five TMs each), intertwined in an antiparallel topology. A substrate 
binding site is located in a nearly identical position at two broken helices, one from each domain. 
The ion binding sites necessary for energy coupling are located close to the substrate binding. 
Hence, there are three conformations caught in among these four homologies (see Figure 5): 
“outward-facing open” (LeuT,57 Mhp1,58),“outward-facing occluded” (vGltPh,43,55 LeuT,57 
Mhp158) and “inward-facing occluded” (vSGLT56). A fourth conformation, corresponding to an 
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inward-facing open can only be hypothetical. This creates a sequence of action to explain how 
the transporter works inside itself. 
 
B C DA
Rigid helices5-HT Flexible helices bundles with
5-HT and ion binding sites
Gate elements
Substrate-induced structural conformations of gated switch transporter
A) The outward-facing open conformation is ready to accept the 5-HT and ion particle.
B) The outward-facing occluded conformation with5-HT bounded and external gate closed.
C) Closure of the external gate drives the inward-facing occluded conformation.
D) The hypothetically inward-faceing conformation open the gate for 5-HT and ion release.
out
in
 
Figure 5. “Rock-switch” mechanism for serotonin transporters (illustration only) 
 
In both open and occluded outward-facing conformations of LeuT and Mhp1, the 
intracellular gate is closed by a considerable protein mass. Similarly, in the occluded inward-
facing conformation of vSGLT, a considerable helical mass closes the extracellular gate. This 
implies that there are two kinds of sequential conformational changes (see the figure). The first 
involves specific gating amino acids or parts of helices located over and below the substrate 
binding site, and the second involves a more massive movement of transmembrane domains, 
which leads to alternating inward- or outward-facing hydrophilic vestibules. 
There is still some crucial details concerning transporter function and mechanism that 
remain unclear, especially how the ion coupling and what is the gating protein. A series of 
11 
 
transporter structures with different bound substrates will be significant to explore these 
unknown regions.59 
 
Serotonin Hypothesis and Antidepressants 
Depressive disorders are one of the most common illnesses in modern society. Every year, 
9.5 percent of the population, or about 18.8 million American adults, suffer from a depressive 
illness.60 It involves human body, mood, and thoughts and is not a “passing blue mood” or a 
weakness of personal character.  Depression not only brings the patient a negative effect on 
mood and motive, but also causes pain and weakens the immune system leading to other 
infectious diseases.  
Although there are many factors can cause depression in varying degrees, biologically, 
depressive disorders are a disease caused by the disrupted serotonergic pathway between the 
neurons.61 The monoamine hypothesis postulates that the deficit of serotonin is responsible for 
the corresponding features of depression. Most antidepressant medications increase the levels of 
one or more of the monoamine neurotransmitters like serotonin, norepinephrine and dopamine in 
the synaptic cleft between neurons in the brain, while some medications affect the monoamine 
receptors directly. 
Tricyclic antidepressants (TCAs) were first discovered in the early 1950s and were 
subsequently introduced later in the decade.62 They are heterocyclic chemical compounds used 
primarily as antidepressants. The TCAs are named after their chemical structure, which contains 
three rings of atoms, like Amitriptyline (4).63 The tetracyclic antidepressants (TeCAs), which 
contain four rings of atoms, are also a closely related group of antidepressant compounds [e.g., 
Amoxapine (5)]. 64 
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 The drawbacks of the TCAs are their side effects. These include drowsiness,65 
restlessness,66 anxiety attacks,67 urinary problems like urinary retention,67 irregular cardiac 
rhythm and other effects.68 Also TCAs overdose is a significant cause of fatal drug poisoning.69 
The severe morbidity and mortality associated with these drugs is well documented due to 
their cardio-vascular and neurological toxicity. Most of side effects are due to their poor binding 
selectivity for the serotonin transporter (SERT) over other transporters like the dopamine 
transporter and the norepinephrine transporter.65-67  
Monoamine oxidase inhibitors (MAOIs,) are another class of antidepressant 
drugs prescribed for the treatment of depression.70 MAOIs act by inhibiting the activity 
of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and 
thereby increasing their availability. The early MAOIs inhibited monoamine oxidase irreversibly. 
When they react with monoamine oxidase, they permanently deactivated these enzymes, and the 
enzyme would function until it had been replaced by the body. This process would take about 
two weeks. A few newer MAOIs, which are reversible inhibitors of MAO-A (RIMA), 
notably Pirlindole (6),71 are able to detach from the enzyme to facilitate usual catabolism of 
the substrate. The level of inhibition in this way is governed by the concentrations of the 
substrate and the MAOIs. 
13 
 
 
 
 
Since MOAIs have no selectivity on reducing the breakdown of most monoamines, they 
have a higher risk of serotonin syndrome or a hypertensive crisis.72 Also tyramine is broken 
down by MAO-A, therefore inhibiting its action may result in excessive build-up of it, so diet 
must be monitored for tyramine intake. Due to potentially lethal dietary and drug interactions, 
MAOIs had been reserved as a last line of defense, used only when other classes of 
antidepressant drugs have failed.  
 
The Serotonin-Selective Reuptake Inhibitors 
 Serotonin-selective reuptake inhibitors (SSRIs) were discovered in the 1980’s as a new 
class of drugs useful for treatment of depression.73 The SSRIs widely replaced tricyclic 
antidepressants (TCAs, e.g. amitriptyline 4) and monoamine oxidase inhibitors (MAOIs, e.g. 
pirlindole 6) as new medications for the treatment of depression. 73-77 
As antidepressants the SSRIs selectively inhibited the reuptake of the neurotransmitter 
serotonin (5-HT) resulting in the increased concentration of extracellular serotonin in the synapse. 
This leads to the therapeutic effect by remediating the disrupted serotonergic pathway that is 
manifested by depression.74-76 As a result of their selective actions on serotonergic mechanisms 
the SSRIs have much improved tolerability, a broader therapeutic index and increased safety 
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towards overdose than TCAs and MAOls.78-80 In addition to the treatment of depression, some 
SSRIs have been recognized as possessing therapeutic value for the treatment of a variety of 
central nervous system (CNS) disorders and disease-states. These include Panic Disorder,81,82 
Post-Traumatic Stress Disorder,83 Social Phobia,84 Obsessive-Compulsive Disorder,85 Pre-
Menstrual Dysphoric Disorder, 86 Anorexia,87 Bulimia76,83 and Schizophrenia.88 
There are five main SSRI-classed drugs (Figure 3) currently on the market and widely 
prescribed for a variety CNS mediated illnesses. 74-76 The most widely prescribed SSRI for the 
treatment of depression is fluoxetine (7, Prozac®).89 The SSRIs paroxetine (8, Paxil®), sertraline 
(9, Zoloft®), citalopram (10, Celexa®), fluvoxamine (11, Luvox®) have all been shown to be 
effective in the treatment of depression. However, due to differences in metabolism (cytochrome 
P450 enzymes) and secondary pharmacology these SSRIs can exhibit varied pharmacological 
profiles among patients.  
 
Figure 6.  Currently Marketed SSRIs  
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Most SSRIs exhibit high selectivity for the serotonin transporter over the dopamine 
transporter (DAT) while somewhat less selective at the norepinephrine transporter (NET). The 
SSRI citalopram (9) is the most selective compound as measured by the in vitro serotonin (5-HT), 
norepinephrine (NE) and dopamine (DA) reuptake inhibition (Table 2).78 However selectivity 
does not necessarily correlate with efficacy. Fluoxetine (7) is generally considered to be the most 
efficacious SSRI but is 94-fold less selective (NE/5-HT) than citalopram (9) and ten-fold less 
selective (NE/5-HT) than paroxetine (7).90 
 
Table 2. SSRIs Inhibition of Monoamine Neurotransmittersa 
SSRI 5-HT (Ki,nM) NE (Ki,nM) DA  (Ki, nM) NE/5-HT DA/5-HT 
Fluoxetine(7) 8 250 1,300 31 163 
Paroxetine(8) 0.2 60 5,400 300 27,000 
Citalopram(10) 2 5800 >10,000 2,900 >5,000 
Sertaline(9) 3 220 440 73 147 
aDerived from data cited in reference 79. 
 
Mechanism of Action of SSRIs 
The SSRIs elicit their pharmacological effects by selectively blocking the serotonin 
recovery system of serotonergic neurons (Figure 4).91 SSRIs bind to the serotonin transporter 
located on the pre-synaptic terminal. The normal function of the serotonin transporter is to 
remove serotonin from the synapse and terminate the serotonergic action. The serotonin 
transporter recovers the serotonin where it is stored in the pre-synaptic terminal until the next 
neurochemical event. By binding to the SERT, the SSRIs block the recovery mechanisms of the 
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SERT thus leading to increased extracellular concentrations of serotonin in the synapse thus 
enhancing post-synaptic serotonin receptor activation. The increased serotonergic transmission 
then remedies the disruption of the serotonin pathways associated with depression and other 
psychiatric disorders.  
 
 
                     
                 Figure 7. Illustrated mechanism of SSRIs activity.  
 
Although the extracellular serotonin level can be simply increased by selective inhibition 
mechanism, it is puzzling that whereas inhibitor block reuptake immediately, alleviation of 
symptom usually requires at least 2-4 weeks.92,93 Many studies reveal this limitation is partially 
due to serotonin autoreceptors. Autoreceptor is a receptor located also on presynaptic nerve cell 
terminals and serves as a part of a feedback loop in signal transduction. For serotonin neuron cell, 
the major autoreceptors are 5-HT1A and 5-HT1B, which are both sensitive to local serotonin 
concentration with different extent. Studies show when autoreceptor 5-HT1A is activated as 
serotonin extracellular level enhanced by SSRIs, it gives negative feedback to the neuron cell 
and decrease release of serotonin from presynaptic cell. While there may be little basal 
endogenous tone at the 5-HT1B autoreceptor sites.94-97 Also research works reveal combined 
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treatment with an SSRI and an autoreceptor antagonist provide a more rapid, and perhaps more 
efficient means of enhancing 5-HT neurotransmission.98,99 While, jointly blocking 5-HT1A and 5-
HT1B autoreceptors has proven without effect on basal 5-HT output, arguing against the 
possibility that a blockade of the former would be offset by an action arising from increased 
activation of the latter, and vice versa.95, 100 Detail mechanism of these autoreceptors still unclear 
and need further study.  
 
The Disadvantages of SSRIs 
Despite many advances in SSRI therapies, as many as 30-40% of patients treated for 
depression with these drugs typically do not respond.74-77 In addition, nearly 50% of those 
patients that do respond never fully achieve complete remission of their depressive symptoms. 
Moreover, many patients using SSRIs experience adverse side effects. These side effects include 
sexual dysfunction,85 increased anxiety, gastrointestinal effects (nausea)101 and insomnia.76 Many 
patients also terminate their medication regiment due to slow-onset of action of the SSRIs.102 In 
clinical environments it can take 2-6 weeks of continuous SSRI administration before 
antidepressant activity can be observed. In late 2004 media attention was given to a proposed 
link between SSRI use and juvenile suicide.103,104 
 Given the plethora of adverse side effects associated with currently available SSRIs there 
clearly remains a need for new SSRI-based drugs with higher efficacy and fewer adverse side 
effects that could be used for treatment of a variety of psychiatric illnesses. 
 
New Targets for Drug Development 
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The SSRIs such as fluoxetine (7) and paroxetine (8) are currently among the most widely 
prescribed drugs for the treatment of depression.75-77 However; recently several new approaches 
have been explored as potential avenues for the treatment of depression and related disorders. 
One approach has been to target the development of serotonin autoreceptor (5-HT1A, 5-HT1B/1D, 
5-HT2A) antagonists.105,106 Co-administration of a 5-HT1A antagonist with an SSRI would then 
lead to shorter induction periods. While there is some evidence that the 5-HT1A antagonist/SSRI 
therapies have enhanced the clinical efficacy of the co-SSRI the results do not clearly mandate 
the abandonment of current SSRI-based therapies. In addition, several dual acting 5-HT1A 
antagonist/SSRI compounds have been identified. The Lilly compound dapoxetine (12 in Figure 
5) has exhibited perhaps the greatest potential as a dual action ligand for the treatment of 
depression and is under investigation.107 
 
N O
H3C
CH3
12
EtO
O
O
N
H
13
HO
N
CH3
H3C
OCH3
14
O
H2N
N
15
O
N
CH3
H
S
16  
                                  
Figure 8. Other Antidepressant Drugs 
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A second approach has been to target compounds with dual SSRI and norepinephrine 
reuptake inhibition (NRI) pharmacological profiles.108,109 It is believed that the efficacy of the 
dual action compounds is achieved via a synergistic effect on the serotonergic and 
norepinephrinergic systems. Compounds such as reboxetine (13),110 venlafaxine (14),111 
milnacipran (15)112 and duloxetine (16)113 all exhibit slightly improved onset of action rates with 
diminished adverse side effects. However, these dual acting SSRI/NRI agents are generally no 
more efficacious and sometimes less efficacious than currently prescribed SSRIs. 
 
Meperidine 
Meperidine (17), commercially marketed under the name Demerol®, was first 
synthesized in 1939 at an IG Farben laboratory as an antimuscarinic agent.114 It was discovered 
that it possessed analgesic effects similar to morphine, by acting as an atypical agonist at the µ-
opioid receptor (Ki = 920 nM).115 For much of the 20th century, meperidine was the opioid of 
choice for many physicians; in 1983 60% of doctors prescribed it for acute pain and 22% for 
chronic severe pain.116 In 1990s, there are multiple reports of a serotonin syndrome observed in 
patients treated with meperidine.117,118 This  serotonin  syndrome which is characterized by 
rigidity, confusion, nausea, diarrhea and coma, has been described in both animals and 
humans.119,120 The following bioassay proved that it has potent binding affinity for the serotonin 
transporter (Ki = 413 nM) and be an inhibitor of serotonin reuptake.121 Meperidine also exhibits 
weak affinity for the dopamine transporter with biphasic reuptake inhibition of [3H]dopamine 
[IC50 = 0.61 ± 2.2 nM (22% of total inhibition)] when examined in a chopped tissue rather than 
synaptosomal preparations.115 Further, the concentration response curve of dopamine reuptake 
inhibition exhibited a plateau at approximately 20% inhibition over a broad range of low 
20 
 
concentrations of meperidine. The maximal inhibition of dopamine reuptake produced by 
meperidine at low concentrations (20%) was also consistent with the maximal inhibition 
associated with the high-affinity binding component (18%) of the selective dopamine transporter 
ligand [3H]WIN 35,428 (18).115 However, structural modification of meperidine has been shown 
to effectively eliminate dopaminergic activity relative to its serotonergic pharmacological 
profile.115 
 
 
 
Meperidine Hypothesis 
Meperidine (17) exhibits high affinity for the serotonin transporter and relative poor 
affinity for the dopamine transporter (Ki = 18,000 nM).115 All the facts observed directed our 
attention to compare the structure of meperidine, serotonin and dopamine to find their structural 
similarities. (Figure 6) From a comparison of geometry-optimized structures, meperidine was 
found share a high similarity with serotonin. The distance between amine nitrogen atom to aryl 
ring was determined to be 4.4-7.1Å for meperidine.122 (see Table 3) This was very similar to that 
calculated for serotonin, 3.8-7.1Å. An overlay of meperidine and serotonin exhibits a good 
match for the ring systems and the amino groups, while there is less of a structural alignment 
with dopamine. This can partially explain why meperidine shows binding differences for the 
serotonin transporter over the dopamine transporter. 
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Based upon these pharmacological results and the structural comparison, meperidine has 
been identified as a lead compound for the development of a novel class of SSRIs. It was 
envisaged that through structural modification of meperidine increased serotonin transporter 
selectively over the dopamine transporter and the norepinephrine transporter can be achieved. 
Structure-activity studies of meperidine analogues at monoamine transporters will lead to 
identification of the necessary functionality for high serotonin transporter selectivity and potent 
serotonin reuptake inhibition, but also improve our understanding of the protein structure of 
these transporters. 
 
 
                            Meperidine                                                                  Serotonin 
 
               Dopamine                                            Overlay of Meperidine and Serotonin 
         
               Figure 9. Structural comparison of Meperidine, Serotonin and Dopamine 
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Table 3. Geometry features comparison of meperidine, serotonin and dopamine 
 
Compound N-Ar Distance (Å)122 
Meperidine 4.4-7.1 
Serotonin 3.8-7.1 
Dopamine 3.9-6.6 
Average 4.1-6.9 
 
 
Lead Modification 
As our lead compound, Meperidine is chemically constructed by attaching a phenyl ring 
to the 4-position of the piperidine ring, and also requires an ethyl carboxylic ester on the 4-
position. Since the carbon-nitrogen ring scaffold of meperidine was determined to be highly 
important for molecular recognition at serotonin transporters from the previous structural 
comparison,30,121 the lead modification will focus on the sub-structures shown in Scheme 1. 
 
 
Scheme 1 
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The first modifications will focus on optimizing the aromatic ring system for transporter 
affinity. The different ring moieties with various substituted groups will be examined for 
serotonin transporter, dopamine transporter and norepinephrine transporter binding affinity and 
selectivity. Also the µ-opioid affinity will be re-examined, since any analgesic effects from 
meperidine is unwanted in SSRI development. 
 The second modification will focus on the functional group transformations at the ester 
moiety. Initially, the ester group will be modified to explore the structure-activity relationships at 
of the alkyl group. Secondly, new functional groups will be explored that could lead to reduced 
lipophilicity and enhanced bioavailabity. 
The last optimization is focused on the amino group which is the most important factor in 
monoamine transporter recognition. Different substituted N-groups will be introduced that do not 
change the basicity of nitrogen atom, but effect the steric environment around the nitrogen atom 
as well as the piperidine ring conformation. 
 
 
Transporter Binding Affinity and Inhibition Constant 
 The potency of compounds for the monoamine transporters are typically given as IC50 or 
Ki value. These values indicate the affinity or ease with which the compound binds to the 
specific transporter; the lower the value, the higher the affinity. Therefore, a compound that 
exhibits high affinity for a transporter binds to that transporter at low concentrations. The 
compounds are compared to a bound radiolabeled ligand that exhibits high affinity for the 
transporter, such as [3H]WIN35,428 (18) for the dopamine transporter, [3H]paroxetine (8) for the 
serotonin transporter and [3H]nisoxetine (19) for norepinephrine transporter. 
24 
 
 
 
   
The IC50 is the concentration at which the compound is needed to displace 50% of the 
radiolabeled ligand. The inhibition constant (Ki ) was derived by Cheng and Prusoff in 1973 and 
is shown in equation (1).123 
  
 
 
[3Hsub] is the concentration of the radiolabeled ligand or substrates, and Kd is the 
dissociation constant of the radiolabeled ligand previously determined for specific transporter. 
By taking the concentration of radiolabeled ligand and the dissociation constant for that ligand 
into account in addition to the IC50 value for the compound being tested, the values are more 
comparable between laboratories. 
 
General Hierarchy of Screening 
Our general screening flow for this project is illustrated as Scheme 2. The analogues from 
each modification step will be screened for the candidates with potency for serotonin transporter 
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(SERT Ki<20nM) and selectivity over the dopamine, norepinephrine transporters (DAT, NET) 
and µ-opioid receptor (>100 times), all the analogues will complete the inhibition assays with the 
radiolabeled ligands in vitro. Then, the new candidates will be sent to next screening level of in 
vitro assays to determine the serotonin, dopamine and norepinephrine reuptake inhibition. The 
most promising compounds from these assays will then be advanced to behavioral assays and 
pharmacokinetic studies. 
 
 
Scheme 2 
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Preliminary Structure-Activity Relationships of Meperidine Analogues 
Novel derivatives of meperidine (17) were synthesized and the binding affinities were 
compared for the dopamine and serotonin transporter,30 as well as the µ-opioid receptors. The 
substituted aryl ring group on the piperidine system was explored for the meperidine system with 
both the nitrile (20a-f) and ethyl ester moieties (21a-f) at the 4-position of the piperidine 
ring.121,124  
 
 
 
The in vitro binding affinities of the aryl derivatives (21a-f) of this series are listed in 
Table 4. In general, these compounds were more potent than the corresponding nitrile derivatives 
(20a-f) at the both transporters.124 The binding affinities for µ-opioid receptor were measured 
against [3H]DAMGO ([D-Ala-N-Me-Phe-Gly-ol]enkephalin). The selectivities of each 
compound for the serotonin transporter relative to dopamine transporter and  µ-opioid receptor 
are listed in Table 5. 
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Table 4. The In Vitro Binding Data at Dopamine Transporter (DAT), Serotonin Transporter 
(SERT), and µ-Opioid Receptor for 4-Aryl-Substituted Meperidines. 
 
 
 
a All compound were tested as HCl salt. b All values are the mean±SEM of three experiments 
performed in triplicate.  
 
 
 
 
 
 
 
 
Cpd Ara [
3H]WIN 35,428 
(DAT) Ki(nM)b 
[3H]Paroxetine 
(SERT) Ki(nM)b 
[3H]DAMGO 
(µ) Ki(nM)b 
17 Ph 17,800±2,670 413±44 920 
21a 4-F-Ph 10,700±2250 308±26 1,470 
21b 4-Cl-Ph 4,100±1270 277±40 4,410  
21c 4-I-Ph 3,250±195 21.0±2.4 2,350 
21d 3,4-Cl2-Ph 125±15 19.0±2.6 2,040  
21e 2-Naphthyl 1140±380 7.20±0.53 2,030  
21f 4-Me-Ph 12,400±5,210 1,610±110 2,670 
28 
 
Table 5. The Binding Selectivity on Serotonin Transporter  over Dopamine Transporter and µ-
Opioid Receptor for 4-Aryl-Substituted Meperidines.  
 
 
 
 
In general, the aryl-substituted meperidine analogues were more selective for the 
serotonin transporter than the dopamine transporter, following the same trend as meperidine (17). 
In particular, the 4-iodophenyl 21c, 3,4-dichlrorophenyl 21d and 4-naphthyl 21e were highly 
selective for serotonin transporter.124 All of the analogues were less selective for the µ-opioid 
receptor than meperidine. These results prompted interest in further studies of meperidine 
analogues to selectively inhibiting serotonin reuptake. 
Other modifications were made on the ester group at the 4-position of the meperidine 
scaffold. These analogues were synthesized by Rhoden et al. via the synthetic route illustrated in 
Cpd Ar DAT/SERT µ/SERT 
17 Ph 43 2.2 
21a 4-F-Ph 34 4.8 
21b 4-Cl-Ph 14 16 
21c 4-I-Ph 154 111 
21d 3,4-Cl2-Ph 6.7 109 
21e 2-Naphthyl 162 281 
21f 4-Me-Ph 7.7 1.7 
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Scheme 3.125  The in vitro binding affinities of the piperidine derivatives (22 - 28) of this series 
are listed in Table 5. 
 
 
Scheme 3 
 
 
Table 6. Binding Data at Serotonin Transporters (SERT) and Dopamine Transporter (DAT) for 
4-(3,4-Dichlorophenyl) 4-Substituted Meperidines. 
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a All values are the mean ± SEM of three experiments performed in triplicate. NT (Not tested). 
 
The results of the dopamine and serotonin binding affinities of the various functional 
group transformations indicated that the ethyl ester moiety of 21d is not necessary for high 
affinity binding to the serotonin transporter. Replace most of the ester moiety with short rigid 
chain showed no improvement on binding affinity at the serotonin transporter. Chain and branch 
alcohols increased selectivity to some extent, due to decreased dopamine transporter affinity. An 
extra electron donor or H-bond acceptor on the 4-position is not favored by the dopamine 
transporter, but still tolerated by the serotonin transporter. These preliminary results provided 
helpful SAR information and pointed out that the ester functional group itself can be maintained 
for the further modification, since it can be easily converted into other derivatives via 
transesterification, reduction and hydrolysis. 
 
 
 
Cmpd R [
3H]WIN 35,428 
(DAT) Ki(nM)a 
[3H]Paroxetine 
(SERT) Ki(nM)a DAT/SERT 
21d CO2CH2CH3 125±15 18.7±2.6 6.7 
28 CH2CH3 163±38 9.1±1.6 18 
24 CH=CH2 192±31 11.4±0.5 17 
25b COPh 253±21 200±18 1.3 
25a COCH3 367±35 35±13 10 
27 CH2OCOCH3 633±91 38±6 17 
26a CHOHCH3 670±39 17±1 36 
26c CHOH(C6H5)2 4590±330 NT NT 
22 CH2OH 3310±210 83±3 40 
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Synthesis of Meperidine 
Meperidine (17) was synthesized in 1939 at an IG Farben laboratory as an anti-
muscarinic agent.114 After its analgesic effect was discovered, meperidine and its derivatives 
have been synthesized using several different methods. Each of the methods has drawbacks due 
to limited substitution potential, highly toxic reagents, number of synthetic transformations, low 
total yields or production of highly toxic intermediates. A synthesis which minimizes the use of 
toxic reagents and intermediates and allows facile substitutions of wide variety moieties with 
better total yields on the meperidine system is ideal for obtaining a full spectrum of compounds 
for structure-activity studies at the dopamine and serotonin transporters. 
Meperidine consists of one benzene ring, one piperidine ring and one ester functional 
group. By examining the structure, two different synthetic routes can be identified by retro-
synthetic analysis as illustrated in Scheme 4. The first route is to the close the piperidine by 
dialkylation of α-carbon of phenyl nitrile; the other way, which seems more straightforward, is 
coupling two ring systems with an organometallic agent and specific catalyst. 
 
Scheme 4 
 
 
The most widely used synthesis, via Route I, involves the reaction of bis(β-
haloalkyl)amines, in particular mechlorethamine (30). However, 30 is considered a highly toxic 
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cancer suspect agent.125,126 This synthesis of meperidine (17) was patented by Otto Eisleb in 
1939 (Scheme 5).125  Other amines can be synthesized as the hydrochloride salt to provide 
various substitutions on the nitrogen; however the amine compounds are severe vesicants and 
must be handled with caution.127 The amines are reacted with phenylacetonitrile(29) and sodium 
amide to give the piperidine ring.  The nitrile can be hydrolyzed with acid and esterified with 
ethanol via Dean Stark Trap to give the meperidine compound.125,126 
 
Scheme 5 
 
 
One variation of the synthesis eliminates the necessity of sodium amide by using sodium 
hydroxide and a phase transfer catalyst, such as hexadecyltributylphosphonium bromide 
(HDTPB) was employed as illustrated in Scheme 6. The hydrochloride salt of the amine 32 (R = 
methyl, ethyl, n-butyl, t-butyl, and phenyl) and m-methoxyphenylacetonitrile (31) in 50% 
sodium hydroxide reacted to give the meperidine nitrile (33).127,128 The disadvantage of phase 
transfer catalyst is that the total yield is highly dependent upon the stirring efficiency, which 
usually causes the reaction mixture to foam up during the course of the reaction.  
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In 1952, Blicke et al. reported a different method to obtain the piperidine ring system of 
meperidine (Scheme 7).129 Phenylacetonitrile(29), sodium amide and β-dimethylaminoethyl 
chloride (34) were reacted to form α,α-di-(β-dimethylaminoethyl)-α-phenylacetonitrile (35). 
Heating 35 at high temperature (270-290°C) furnished the meperidine nitrile hydrochloride 
(20).129  This method limits N- substitution based on the nature of the ring-closing step. 
 
Scheme 7 
 
 
Another approach employed by Smisson et al. was to use a quasi-Favorskii 
rearrangement (Scheme 8).130 This method is considerably longer and limited in the manner of 
facile substitutions of various moieties including aryl substitutions and nitrogen substitutions. 
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Isonicotinic acid (36) was methylated with methyl iodide followed by the use of an ion-exchange 
column to give 38. Hydrogenation afforded the piperidine ring (39), which was then reacted with 
thionyl chloride, to give the acid chloride. The acid chloride was converted into 1-methyl-4-
benzoyl-piperidine hydrochloride (40) via the Friedel-Crafts reaction with aluminum trichloride 
and benzene. Chlorination afforded the di-substituted piperidine ring (41). Treatment with 
sodium hydroxide and xylenes gave a mixture of the ketone (42) and 1-methyl-4-phenyl-4-
piperidingcarboxylic acid (43). Esterification of 43 using hydrochloric acid and ethanol gave 
meperidine hydrochloride (21) in an overall yield lower than10%.130 
 
Scheme 8 
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Also a more straightforward method via Route II, is direct coupling the aromatic ring 
with the piperidine via Grignard method (Scheme 9). The  Grignard reagent phenylmagnesium 
bromide  was reacted with 1-methylpiperidin-4-one (45) and afforded a 30% yield of target 
product  1-methyl-4-phenylpiperidin-4-ol (46), and a 25% yield of the byproduct 1-methyl-4-
phenyl-1,2,5,6-tetra-hydropyridine (MPTP, 47), because the tertiary alcohol is liable to 
dehydration under acidic conditions if the reaction temperature rises above -30 °C. MPTP has 
been found to produce Parkinson’s-like symptoms, making this synthetic sequence and the 
handling of the intermediate compound quite unattractive.131-133 One case in particular involved 
the development of Parkinson-like symptoms in a 37-year old chemist who had worked with the 
compound for eight years.134 Also in 1982, seven people were diagnosed with Parkinson-like 
symptoms after having used 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP, 48), an illegal 
recreational drug, contaminated with MPTP. Eventually the motor symptoms of two of the seven 
patients were successfully treated.135 
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In 2002, Hartwig et al. publish a new coupling method for α-arylation, which connect 
aryl ring directly to the α-carbon of activated esters or ketones.141 (Scheme 10) According to the 
published paper, the yields are highly depend on the start materials  as well as optimized base  
ligand pair and  optimized solvents. In 2007, similar work was published from from a Pfizer 
laboratory.142 In their publish paper, only N-BOC protected piperidines, with electron-deficient 
pyridine halides were applied with variable yields. 
 
Scheme 10 
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Acetal Pathway for Meperidine Synthesis 
Since the direct coupling route was determined to be low yielding and produced an 
inevitably toxic by-product and alternative approach was investigated. In 1999, a new synthesis 
pathway was designed and developed by Lomenzo, et al. (Scheme 11).121 This synthesis 
provided a facile method of incorporating various aryl substitutions on the meperidine scaffold, 
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while keeping toxic reagents and intermediates to a minimum. Improvements to the synthesis 
were achieved to make it more efficient for large scale. Specifically, the ring closure step was 
targeted. 
 
Scheme 11 
 
 
Objectives and Specific Aims 
Based on the previous SAR studies of meperidine analogues, we have clearly identified a 
new class of serotonin transporter selective ligands (21c,d,e).121 These preliminary studies 
demonstrated the potential for the development of meperidine—based SSRIs with diminished µ-
opioid receptor affinity. The serotonin transporter binding affinity data obtained for these 
meperidine derivatives (21c,d,e) indicate that serotonin transporter reuptake inhibition should be 
both potent and selective over dopamine transporter and norepinephrine transporter. 121  
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Although structural modifications on norepinephrine reuptake inhibition (NRI) have yet 
to be determined, NRI will probably not be significant since the meperidine analogues generally 
exhibited very poor affinity for the norepinephrine.121 Moreover, the dopamine uptake inhibition 
may be selectively diminished by simple structural modifications of the aryl group and ester 
group.   
We realized that the preliminary SAR was rather limited in scope and far from optimized. 
Nevertheless based on the serotonin transporter selectivity observed for these compounds, we 
were encouraged that a novel meperidine-based SSRI could be developed with therapeutic value 
for the treatment of a variety of psychiatric disorders.  
The objective of the proposed research is to synthesize and evaluate the preclinical 
biological and behavioral effects of novel compounds targeted for the serotonin transporter. 
These compounds are designed to further elucidate the structure-activity relationships of 
serotonin transporter ligands as well as provide leads toward the development of new therapeutic 
SSRIs for the treatment of depression and related psychiatric disorders. To achieve these 
objectives the proposed areas of research are described in the following sections. 
 
Specific Aim I: To design, synthesize and evaluate the 4-aryl-4·carboethoxy-
piperidines as potential SSRIs. 
A series of 4-aryl-4-carboethoxy-piperidines are to be synthesized. The initial focus of 
the proposed study will be to complete the SAR study described in the Introduction Section. This 
will require the synthesis of the analogues (21c,d,e) for evaluation of the norepinephrine affinity, 
monoamine reuptake inhibition (dopamine, serotonin, and norepinephrine), as well as µ-opioid 
receptor affinity. In addition to these analogues, the SAR of the aryl ring of meperidine will be 
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explored further by the preparation of a variety of novel 4-aryl meperidine derivatives (21). It has 
been shown that increased lipophilicity on the aryl ring of 3-phenyl tropane derivatives led to 
enhanced serotonin transporter selectivity over dopamine transporter and norepinephrine 
transporter.136-140 Since the SAR of the meperidine analogues has been shown to parallel the 
SAR of the 3-phenyltropanes many of the target compounds have aryl substitution patterns that 
have been shown to favor the serotonin transporter over the dopamine transporter and the 
norepinephrine transporter. 
 
Specific Aim 2: To design, synthesize and evaluate 4-aryl-4-substituted meperidine 
derivatives as potential SSRIs. 
A series of 4-aryl-4-substituted piperidine analogues that possess a variety of functional 
groups at the 4-position of 4-aryl-piperidines identified in Specific Aim 1 will be synthesized. 
The focus of this study will be to optimize the SAR of the ester moiety to enhance SERT 
selectivity over DAT and NET. As described in the Preliminary Results Section, replacing the 
ester group with other function groups did not enhance SERT selectivity relative. Therefore, for 
potent 4-aryl-carboethoxypiperidine derivatives (21) in Specific Aim 1, a series of ester 
analogues will be prepared. The initial focus of this study will be the preparation of benzyl esters. 
 
Specific Aim 3: To design, synthesize and evaluate N-Demethylated 4-aryl-4-
substituted meperidine derivatives as potential SSRIs. 
Based on early SAR studies of N-substituted meperidine analogues, substituent group on 
N-atom will exhibit serotonin transporter affinity dramatically decreased due to increased steric 
hindrance and rigid amino conformation. However, some N-demethylated analogues (21) exhibit 
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higher serotonin transporter selectivity over dopamine transporter and norepinephrine 
transporter.125 Hence, N-demethylated analogues, which combine with optimized functional 
groups from aim 1 and 2, will be explored. 
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RESULTS AND DISCUSSION 
 
Since the discovery of the analgesic effects of meperidine, various methods for the 
synthesis of meperidine and meperidine derivatives have been reported. 127-134,121 As we 
introduced and compared in previous section, several of the methods involve the use of toxic 
reagents or intermediates.125-129,131-134 Other syntheses either involved a number of synthetic 
transformations or were limited in potential substitutions. To meet the objectives of this project, 
a synthesis that involved user- friendly reagents, the potential for incorporating a wide variety of 
substitutions and efficient in nature to produce a large number of analogues as well as large scale 
production of select analogues would be desirable. The synthesis reported by Lomenzo et al.121 
meets several of these requirements: 1) toxic reagents and intermediates are kept to a minimum; 
2) various substitutions can be afforded in different steps of the synthesis and; 3) the five-step 
sequence can provide useful quantities from commercially available starting materials. As 
illustrated in Scheme 10, the synthetic sequence begins with dialkylation of an arylacetonitrile 
derivative 29 with bromoacetaldehyde dimethyl acetal to furnish the bisacetal 55. Acid 
hydrolysis of 55 gives the dialdehyde and concomitant reductive amination provides the nitriles 
20. Hydrolysis of the nitriles 20 gives the carboxylic acid, followed by esterification with an 
alcohol to afford various esters 21. 
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Attempted Alternative Meperidine Synthesis 
  Early experiments in our lab using mechlorethamine were successful to close the ring 
with good efficiency providing the meperidine derivatives in 50% yields. However, in order to 
avoid the toxic start materials, diethanolamine (56) was used as the starting material instead of 
mechlorethamine in Scheme 12, following the tosylation to convert both hydroxyl and amino 
groups into a sulfonate and sulfamide groups, respectively. The tosylated amine 57 should 
decrease the nitrogen basicity and nucleophilicity and lead to lower toxicity than that of 
mechlorethamine. However, when the following ring closure step was conducted with sodium 
amide, initially only monoalkylated phenyl acetonitriles (59) were obtained. Different bases like 
sodium hydride, lithium diisopropylamide and n-butyllithium were tested in parallel with 
different solvent systems, temperatures, reaction times and starting material concentrations 
(Table 7). Unfortunately the major product was consistently found to be mono-alkylated phenyl 
acetonitrile (59), and only <10% of the piperidine nitrile (58) was afforded. The carbon anion is 
observed after addition of base, but the alkylation stopped after one side chain was attached. 
Extended reaction times were unsuccessful and only the mono-alkylated nitrile (59) was 
observed after heating for 2 days, even in diluted systems. Also the further attempts to form the 
piperidine rings by using purified mono-alkylated nitrile (59) and base-promoted ring-closing 
conditions to effect the ring closure were unsuccessful and afforded low yields (<10%) of 
piperidine nitrile (58). Unreacted starting materials were observed and a mixture of intractable 
material was observed. The failure to close this ring was possibly due to the sulfamide group, 
which results in increased ring strain and making it difficult for the other side chain to be 
attacked by nitrile α-carbon anion.  
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Table 7.Various conditions for ring closing step of 57 and 59 
Base Solvent Temp. (°C) Conc. (M) 
NaNH2 Toluene/Ether -23°C-r.t, then reflux 
0.1M 
0.2M 
0.3M 
NaH THF/Toluene 0°C-R.T, then reflux 
LDA CH3CN/THF -78°C-r.t  then reflux 
n-BuLi THF 0°C-r.t, then reflux 
 
 
According to the published method from Hartwig’s group,141 a couple of trails were 
carried out as illustrated Scheme 12. The procedure was carried out in glove box under a dry 
Argon atmosphere. A solution of the ester 61 (1.1 mmol) in toluene (2 mL) was added to a vial 
containing 1.3 equiv of LiNCy2 (1.3 mmol). The solution was stirred for 10 min before it was 
transferred to a screw-capped vial containing a catalytic amount of Pd2(dba)3 and the aryl halide 
(1.0 mmol). Finally, P(t-Bu)3 was added from a 0.5 M toluene stock solution. The vial was fitted 
with a PFTE septum and removed from the glove box. The reaction mixture was stirred at room 
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temperature for 24 h. The target product methyl 1-methyl-4-phenyl-4-carboxymethylpiperidine 
(62) was observed by GC-MS however with low yields (< 10%), the homo-coupling byproduct 
and unreacted ester were also present. The result can possibly explained by the low reactivity of 
phenyllithium and the potential catalyst poisoning by basic piperidine nitrogen. This analysis 
was supported by the research work from a Pfizer laboratory.142 Only N-BOC protected 
piperidines, with electron-deficient pyridine halides were applied with variable yields.  
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N
+
Br
O
OMe
H
LiNCy2, Pd2(dba)3, (t-Bu)3P
toluene, Ar, r.t.
60 61
N
O
OMe
62
yields<10%
Cl
Cl
 
 
 
 
Attempted Modification of Ring Closure Step 
Since our attempts to develop new method for synthesis meperidine were successful. 
Attention focused on the optimization of acetyl synthetic pathway. It was evident that the 
synthesis shown in Scheme 11 would require increased efficiency for large-scale synthesis of the 
target aryl-substituted meperidines in order to obtain the desired gram quantities for behavioral 
studies. In particular, the ring closure step, which typically gave the piperidine ring products in 
moderate yields (30-50%), was targeted.  
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A search of the literature revealed that the deprotection of acetals using trimethylsilyl 
iodide afforded the corresponding aldehydes.143 Previous attempts of using this deprotection 
method to obtain the dialdehyde product 63 from the diacetal compound 55 (Scheme 14). 
Propene was bubbled into chloroform followed by addition of iodotrimethylsilane and the 
diacetal 55. (The use of the propene was necessary to eliminate the hydrogen iodide formed from 
the reaction of iodotrimethylsilane with moisture in the air. The resulting product, isopropyl 
iodide, could then be easily removed in vacuo.) The solution was allowed to stir for up to 75 
minutes at room temperature. No evidence of the dialdehyde product 63 was detected by thin 
layer chromatography. It was determined by 1H NMR and MS that the major product was 
actually a substituted pyran 64 obtained in 77% yield. It is thought that the proximity of the 
diacetals allows for favorable intramolecular ring closure to form a pyran ring upon formation of 
an intermediate hemiacetal. 
 
Scheme 14 
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Purified byproducts of the original deprotection/reductive amination method revealed a 
similar pyran ring system 65 had been formed in the hydrolysis of 55 (Scheme 10). The pyran 65 
was obtained in 33% yield with a 35% yield of the desired nitrile 20. With trails of different 
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conditions and reactant amounts, the optimized yield of 50% can be achieved with fresh made 
3N HCl for hydrolysis and three equivalents of methylamine HCl for the reductive amination.  
Attempts to hydrolyze the pyran 65 revealed that it was necessary to increase the reaction 
temperature to reflux to afford the desired dialdehyde. Subsequent reductive amination furnished 
the piperidine ring 20 in only 30% yield (Scheme 15). Presumably the higher reaction 
temperature required for the hydrolysis also led to hydrolysis of the nitrile moiety as well, 
leading to the low overall yield of 20. 
 
Scheme 15 
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At this point it was determined that the original synthesis using the acetyl pathway could 
be scaled up enough to obtain gram quantities of the desired meperidine derivatives despite the 
modestly efficient ring closing sequence. The proximity of the diacetal moieties led to 
intramolecular ring-closure competition using the iodotrimethylsilane deprotection method and 
would more than likely be problematic using other deprotection methods as well. Alternatively, 
harsh conditions for the hydrolysis of the diacetals increased the risk of by-products such as 
hydrolysis of the nitrile. Performing the initial hydrolysis at 80 °C gave multiple products by thin 
layer chromatography and it can be assumed that use of a stronger acid would also give multiple 
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products. Also treating the diacetal nitrile with strong acid and  higher temperatures to make the 
dialdehyde with a carboxylic acid, or even straight to esterification step was assumed to be 
problematic due to too many possible byproducts like amino acid, amide and dehydrated pyrans, 
which will diminish the overall yield and add potential difficulty to the work up and purification 
steps.    
 
Synthesis of Aryl-substituted Meperidine Derivatives 
A series of aryl-substituted meperidine derivatives were chosen to be synthesized and 
tested for in vitro binding affinity. These compounds were chosen for their high affinity or 
selectivity for the serotonin transporter relative to meperidine. The desired variations of aryl 
moieties could be obtained as illustrated in Scheme 16.  
The dialkylation of 2-aryl acetonitriles 29a-h with sodium amide and bromoacetaldehyde 
dimethyl acetal in dry toluene gave the corresponding diacetals 55a-h in good yields (65-80%). 
The diacetals 55a-h were then deprotected via acid hydrolysis using 3N hydrochloric acid at 
50 °C followed by reductive amination with methylamine hydrochloride and sodium cyano-
borohydride in dry methanol to obtain the piperidines 20a-h. This two-step process afforded the 
4-aryl-4-cyano piperidines 20a-h in moderate overall yields (30-50%). The nitriles 20a-h were 
converted into the corresponding ethyl esters 21 first by hydrolysis with aqueous sulfuric acid at 
120 °C to obtain the carboxylic acid, followed by addition of excess ethanol to the reaction 
mixture. Azeotropic distillation of the ethanol/water afforded the ethyl esters 21a-h in good 
overall yields (50-80%). 
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Scheme 16 
 
Biological Studies of Dopamine Transporter, Serotonin Transporter, Norepinephrine 
Transporter and µ-opioid Binding Affinities of Aryl-substituted Meperidine Derivatives (21) 
The binding assays were performed by Dr. Sari Izenwasser at the University of Miami 
School of Medicine. The binding affinities for monoamine transporters and µ-opioid receptor are 
reported as Ki values and listed in Table 8 and Table 9. 
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Table 8. The In Vitro Binding Data at Dopamine Transporter (DAT), Serotonin Transporter 
(SERT), Norepinephrine Transporter (NET) and µ-Opioid Receptor for 4-Aryl-Substituted 
Meperidines. 
 
 
 
a All compound were tested as HCl salt. b All values are the mean±SEM of three experiments 
performed in triplicate. c Percent inhibition at highest dose tested (100µM). d Percent inhibition at 
highest dose tested (10 µM). NT, Not tested. 
 
 
 
 
 
 
Cpd Ar [
3H]WIN 35,428 
(DAT) Ki(nM)b 
[3H]Paroxetine 
(SERT) Ki(nM)b 
[3H]Nisoxetine 
(NET) Ki(nM)b 
[3H]DAMGO 
(µ) Ki(nM)b 
17 Ph 17,800±2,670 413±44 NT 920 
21a 4-F-Ph 10,700±2250 308±26 (71.9)d 1,470 
21b 4-Cl-Ph 4,100±1270 277±40 601,000±45,900 4,410 
21c 4-I-Ph 3,250±195 21.0±2.4 519,000±51,100 2,350 
21d 4-Br-Ph 6,601±137.6 48.6±6.1 NT NT 
21e 3,4-Cl2-Ph 125±15 19.0±2.6 74,500±5,100 2,040 
21f 2-Naphthyl 1140±380 7.20±0.53 71,100±9,700 2,030 
21g 4-Ph-Ph 6,800±3,000 43.0±8.0 4,820±632 4,390 
21h 4-Me-Ph 12,400±5,210 1,610±110 (57.6)d 2,670 
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Table 9. The Binding Selectivity on SERT over DAT, NET and µ-Opioid Receptor for 4-Aryl-
Substituted Meperidine Compounds. 
 
 
 
Cpd Ar DAT/SERT NET/SERT µ/SERT 
17 Ph 43 -- 2.2 
21a 4-F-Ph 34 -- 4.8 
21b 4-Cl-Ph 14 2,170 16 
21c 4-I-Ph 154 24,700 111 
21d 4-Br-Ph 136 -- -- 
21e 3,4-Cl2-Ph 6.7 3,920 109 
21f 2-Naphthyl 162 9,880 281 
21g 4-Ph-Ph 158 112 102 
21h 4-Me-Ph 7.7 -- 1.7 
 
In general, the substituted aryl ring improved the serotonin transporter binding potency 
and selectivity, except compound 21h, which bearing 4-methyl group as an electron-donating 
substituent. For the analogues containing an electron-withdrawing substituent, the serotonin 
transporter binding affinity improved with larger substituent, such as 4-I-phenyl (21c), 3,4-Cl2-
phenyl (21e), 2-naphthyl (21f), and 4-biphenyl (21g) analogues. Also the µ-opioid receptor 
binding affinity was dramatically diminished by larger substituent. For norepinephrine 
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transporter binding, these meperidine analogues show poor affinities and can be considering not 
relative.  
The results of this SAR study gave us the picture that there must be a large hydrophobic 
pocket at serotonin transporter that can accommodate a large substituent on the aryl ring (e.g.  
analogues 21c,e,f,g). The 3-D models of these candidates are shown below to illustrate these ring 
features (Figure 10). 
 
 
 
   Figure 10. Structure comparison of Meperidine Analogues (21c,e,f,g). 
 
Also the bioavailability properties of these analogues are also summarized in Table 10. 
Both partition coefficient (ClogP) and topological polar surface area (tPSA) data are calculated 
and compared.144  CLogP and tPSA  are important index for predict a drug’s possibility to pass 
through cell membranes and blood brain barriers. Usually the tPSA should be lower than 140 
angstroms square (Å2) for the drug penetrate cell membranes and lower than 60 angstroms 
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square to pass the blood-brain barriers, 145 also the drug candidate with ClogP <5 will be able to 
pass the blood-brain barriers ,according to Lipinski’s rule of five.146 
 
Table 10. CLog P and tPSA properties of meperidine analogues 21c, e, f, g 
Cmpd.No. CLogP Topological Polar  Surface Area,144 (Å2) 
21c 3.35 29.54 
21e 3.53 29.54 
21f 3.40 29.54 
21g 4.11 29.54 
 
Among of those aryl rings, 4-I- phenyl (21c), 3,4-Cl2-phenyl (21e), 2-naphthyl (21f),and 
4-biphenyl (21g) analogues, which exhibit high potency and selectivity, will serve a new leads to 
the next level of structure modifications. Also all the analogues present good bioavailability with 
low CLogP and tPSA prediction. The 3,4-Cl2-phenyl derivative 21e was selected as the primary 
lead for further optimization due to the relative ease it could be synthesized and the availability 
of gram quantities. 
  
Synthesis of Substituted Benzyl 1-methyl-4-aryl-4-carboalkoxy-piperidine 
Based on the earlier work of Rhoden et al., the binding data of 4-aryl-4-substituted 
meperidine analogues exhibited no positive effects on serotonin transporter binding and 
selectivity.125 In other words, modification of the ester moiety into other functionalities did not 
significantly improve serotonin transporter binding compared to the ester moiety. Hence, our 
next task focused on different esters possessing different alkyl groups and different substituted 
benzyl group. 
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  Due to the high boiling points of some alkyl alcohol or crystalline nature of the 
substituted benzyl alcohols, the hydrolysis and esterification process in Scheme 10 were not 
successful. The N-heterocyclic carbene catalyst work from the laboratories of Professor Steve 
Nolan  appeared to be well suited for this transformation. We choose to apply this novel trans-
esterification method illustrated as Scheme 16, to obtain our desired ester analogues.147-149 
Based upon the literature, the 1,3-bis(cyclohexane) imidazol-2-ylidene (ICy) N-hetero-
cycliccarbene  catalyst was identified as the best catalyst for the  3,4-dichlorophenyl meperidine 
system. Using a fluoroboric acid salt of ICy 66 the N-heterocycliccarbene catalyst was form in 
situ by adding potassium tert-butoxide (9.5 mol%), and activated molecular sieves. The reaction 
was performed in tetrahydrofuran at room temperature for 1-3 days and gave the desired esters 
67a-f with isolated 50% yield or 70% by GC. The low isolated yield is due to the similar polarity 
of both esters 21 and 67.  All of the products show the same spot on TLC plate, it could only be 
separated with long thin column using SiO2 and 10% MeOH in CHCl3.  
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Scheme 17 
 
  
While the transesterification method worked well for the formation of alkyl esters, further 
application of this method for some substituted benzyl alcohols like 4-nitro, 4-methoxy, 4-phenyl 
and 3, 4-dichloro groups gave low yields (10% to 30%) of the corresponding benzyl esters. Even 
with prolonged reaction times of up to 5-7 days and higher catalyst loading (5%-10%), the yields 
did not improve.  The source of the low yield is presumably due to the lower nucleophilicity of 
the oxygen of the substituted benzyl alcohols.  
Generally problems encountered during transesterification arise from equilibration.150 
There is plethora of methods to bias the equilibrium to the product side. Comparing to several 
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other strategies and attempts, the acid chloride pathway as illustrated in Scheme 18 gave  
moderate overall yields, about 55%, with easy purification of the final ester compound. In this 
route, basic hydrolysis of the piperidine nitriles (20) was chosen because of higher yields, easy 
purification and avoiding potential piperidine ring opening. Released ammonia gas NH3 can be 
detected by wet pH paper as a monitor for reaction progress. The 4-aryl-4-carboxylic acid 
piperidine analogues (43) were afforded by recrystalization as the HCl salt, with 92% yield. 
Thionyl chloride was used to convert the carboxylic acids into the corresponding acid chlorides. 
Employing thionyl chloride for this step required careful handling and waste control, due to its 
corrosive nature and irritating smell.  To this end we designed a simple but effective device to 
absorb and HCl fumes produced by the reaction. After removing all the thionyl chloride at 
100 °C, the mixture was cooled down and dried by a continuous flow of N2. The following 
esterification employed a heterogeneous system of aqueous NaOH and dichloromethane. Tetra-
butylammonium bisulphate was used as a phase transfer catalyst and the esterification gave the 
product 67 in 50% yields for the two step process. Other phase transfer agents like 18-crown-6 
ethers and tetra-butyl ammonium bromide were also explored for this reaction, but gave 
significantly lower yields of the desired benzyl esters.   
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Scheme 18 
 
 
 
Biological Studies of Dopamine Transporter, Serotonin Transporter, and Norepinephrine 
Transporter Binding Affinities of 4-Aryl-4-carboalkoxy meperidine Derivatives (67) 
The binding assays were performed by Dr. Sari Izenwasser at the University of Miami 
School of Medicine. The binding affinities for monoamine transporters and µ-opioid receptor are 
reported as Ki values and are listed in Table 11. 
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Table 11. The In Vitro Binding Data at Dopamine Transporter (DAT), Serotonin Transporter 
(SERT) for 4-Aryl-4-Substituted Meperidines. 
 
 
 
aAll compound were tested as HCl salt. b All values are the mean±SEM of three experiments 
performed in triplicate. 
 
From the above data, the benzyl ester congeners generally exhibited better serotonin 
transporter affinity and selectivity than alkyl esters. Among the benzyl ester congeners, 
Cmpda Ar R [
3H]WIN 35,428 
(DAT) Ki(nM)b 
[3H]Paroxetine 
(SERT)Ki(nM)b 
DAT/ 
SERT 
21e 3,4-Cl2-Ph CH2CH3 125±15 19±2.6 6.6 
21i 3,4-Cl2-Ph CH3 383±32 15±1.1 26 
67a 3,4-Cl2-Ph CH2CH2CH3 449±94 16±0.7 27 
67b 3,4-Cl2-Ph CH2CH2CH2CH3 864±114 16±2.5 54 
67d 3,4-Cl2-Ph CH(CH3)2 271±51 43±7.0 6.3 
67e 3,4-Cl2-Ph CH(CH3)CH2CH3 283±11 44±4.7 6.4 
67g 3,4-Cl2-Ph CH2C6H5 917±138 9.2±3.1 100 
67h 3,4-Cl2-Ph CH2C6H5-4-Br 2563±47.8 7. 0±0.9 366 
67i 3,4-Cl2-Ph CH2C6H5-4-I 3471±237.8 13.2±1.8 262 
67j 3,4-Cl2-Ph CH2-naphthyl 4913±525.2 9.9±3.7 496 
67k 3,4-Cl2-Ph CH2C6H5-4-phenyl 5629±508 10.9±2.1 516 
67l 3,4-Cl2-Ph CH2C6H5-3,4 Cl2 5,230±152 4.3±0.5 1,215 
67m 3,4-Cl2-Ph CH2C6H5-4-NO2 1,530±334 1.0±0.10 1,530 
67n 3,4-Cl2-Ph CH2C6H5-4-OMe 2792±626.4 1.7±0.2 1642 
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substituted benzyl ring with 3,4-Cl 67l, 4-NO2 67m, 4-OMe 67n exhibited higher potency and 
selectivity.  
 
 
 
 
      Figure 11. Structure comparison of meperidine analogues 67m, 67n, and Paroxetine  
 
Table 12. Structual summary of meperidine analogues 67m, n, and Paroxetine122 
Compound N-Ar
1 
 Distance (Å) 
N-Ar2 
 Distance (Å) 
Ar1-Ar2 
 Distance (Å) 
67m 4.4-8.8 6.4-10.4 8.0-10.1 
67n 4.4-8.8 6.7-10.9 8.3-9.6 
Paroxetine 3.9-7.5 5.3-8.9 8.5-10.6 
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From the SAR studies, a second aromatic ring appears important for SERT recognition.  
In addition, a strong H-bond acceptor substituent on the benzyl ester is favored. As illustrated in 
Figure 11 and Table 12, the computational comparison 67n, 67m and Paroxetine revealed that 
these molecules share similar structural geometry features. The aryl groups of the ester lies in the 
same domain as the benzodioxole group of paroxetine.  
 
 
Synthesis of N-Demethylated Benzyl 1-methyl-4-aryl-4carboalkoxy-piperidine 
The previous SAR studies from our group showed that the N-substituted meperidine 
analogues exhibit diminished serotonin transporter binding affinity.125 However the N-
demethylated piperidine analogue showed slight improvement of serotonin transporter binding 
affinity and apparently better selectivity. It was noteworthy, that most current market SSRIs 
possesses a secondary amine group Figure 12.  
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            Figure 12. Secondary amines in current market SSRIs.  
 
Based on the above analysis, all the potent candidates that had passed previous screening 
would be demethylated using our established method (Scheme 19). The target compounds are the 
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combination of previous screening candidates, 3,4-Cl2-phenyl, 4-I-phenyl and 2-naphthyl, 
combined with the three potent benzyl esters groups, 4-OMe benzyl, 4-NO2 benzyl and 3,4-
dichloro benzyl. 
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68c: Ar= 4-I-Phenyl;R=4-OMe-Benzyl
68d: Ar=2-Naphthyl;R=3,4-Cl2-Benzyl
68e: Ar= 2-Naphthyl;R=4-NO2-Benzyl
68f: Ar= 2-Naphthyl;R=4-OMe-Benzyl
 
 
Biological Studies of DAT, SERT, and NET Binding Affinities of Benzyl 4-Aryl- 4-
Carboxylate N-Substituent Piperidine Derivatives (69a-j) 
The binding assays were performed by Dr. Sari Izenwasser at the University of Miami 
School of Medicine. The binding affinities for monoamine transporters are reported as Ki values 
for the N-demethylated analogues are listed in Table 13. 
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Table 13. The In Vitro Binding Data at Dopamine Transporter (DAT), Serotonin Transporter 
(SERT), and Norepinephrine Transporter (NET) for 4-Aryl-4-carbobenzyloxy piperidines (68l-
n,69a-j). 
 
21c 4-I-Ph -- H 3,500±321 21.6±1.6 NT 162 -- 
69d 4-I-Ph 3,4-Cl2 H 4,342±1089 5.9±2.7 
6,059 
±1598 736 1027 
69e 4-I-Ph 4-NO2 H 1,777±265 5.9±2.0 
2,069 
±322 301 351 
69f 4-I-Ph 4-OCH3 H 2,925±626 0.6±0.2 
2,731 
±698 4875 4552 
21f 2-Naphthyl -- H 710±138 2.5±0.8 NT 284 -- 
69g 2-Naphthyl 3,4-Cl2 H 3,212±311 26.5±2.4 16,557 ±4034 121 625 
69h 2-Naphthyl 4-NO2 H 732±132 2.0±0.5 937±7 366 469 
69i 2-Naphthyl 4-OCH3 H 889±463 2.9±0.2 2,349 ±127 307 810 
aAll compounds were tested as oxylate salts. bAll values are the mean±SEM of three experiments 
performed in triplicate. NT means not test. 
 
Cpda Ar X R DAT Ki(nM)b 
SERT 
Ki(nM)b 
NET 
Ki(nM)b 
DAT/ 
SERT 
NET/ 
SERT 
68l 3,4-Cl2-Ph 3,4 Cl2 CH3 5,230±152 4.3±0.5 NT 1,215 - 
69a 3,4-Cl2-Ph 3,4 Cl2 H 2,892±715 30.2±4.5 11,930±1060 96 395 
68m 3,4-Cl2-Ph 4-NO2 CH3 1,530±334 1.0±0.10 NT 1,530 - 
69b 3,4-Cl2-Ph 4-NO2 H 1,295±263 3.7±1.2 
10,190
±701 350 2754 
68m 3,4-Cl2-Ph 4-OCH3 CH3 2,792±626 1.7±0.2 299.9 ±29 1642 176 
69c 3,4-Cl2-Ph 4-OCH3 H 1,264±142 4.5±0.9 12,109±931 280 2690 
69j 3,4-Cl2-Ph 4 CF3 H 2,244±200 46.7±17 7,902 ±896 48 196 
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From above data, we observed N-demethylated meperidine analogues (69) generally 
exhibited improved serotonin transporter affinity and selectivity. Analogue 69f showed the 
highest potency and selectivity in the meperidine derivatives, which exhibited sub-nanomolar 
binding affinity and great than 4500 times selectivity for the serotonin transporter. Compared to 
the our initial lead compound, meperidine (17), compound 69f is 700 times more potent and 100 
times more selective for the serotonin transporter (Figure 13). Also comparing to the marketed 
drug Prozac®, [fluoxetine (7)], 69f still shows at least ten-fold greater potency and 30-fold 
increased selectivity over dopamine transporter binding and 150 fold over norepinephrine 
transporter.  This compound will be advanced to in vivo behavioral studies for evaluating as a 
potential antidepressant. 
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Figure 13. Comparison of potency and selectivity of analogue 69f with meperidine and 
fluoxetine. 
 
 
Design of Next Generation SSRIs  
Although we have done the optimization and obtained a promising candidate for in vivo 
behavioral tests, we always keep “Lipinski’s Rule of Five” for blood brain barrier permeability 
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in mind throughout our design and development.146 The rule of five is the basic guideline to 
evaluate druglikeness, or determine if a chemical compound with a certain pharmacological or 
biological activity has properties that would make it a likely to pass through the blood-brain 
barriers in humans. Over the past decade Lipinski's profiling tool for druglikeness has led to 
further investigations by scientists to extend profiling tools to lead-like properties of compounds 
in the hope that a better starting point in early discovery can save time and cost.re According to 
Lipinski’s rules, a CNS active drug has no more than one violation of the following criteria:  
1. Not more than 5 hydrogen bond donors.  
2. Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms). 
3. A molecular weight under 500 daltons (better from 160-480). 
4. An octanol-water partition coefficient log P of less than 5. 
Drug candidate 69f possesses a molecular weight of 451.30 and CLogP value of 4.686, 
which are close to the boundary lines of the Rule of Five (illustrated in Figure 14). Hence, 
lowering the molecular weight and CLogP of next the candidate should lead to improved blood 
brain permeability and potential efficacy. Also the ester functional group in 66f is liable to 
hydrolysis that might lead to a short pharmacological half-life. The half-life is an 
important pharmaco-kinetic parameter in drug development, which indicate how long the drug 
will maintain its pharmacological activity in human body. Here we designed N-benzyl-1-(1-
methyl-4-phenylpiperidin-4-yl) derivatives as the next generation SSRIs. With the replacement 
of ester group by less metabolically liable amino group, the half life is assumed to be extended 
while the amino group still participates as potential H-bond acceptor/donor and provides chain 
flexibility. In addition, the conversion of diamine to dihydrochloride salt, the diamine congeners 
would be expected to exhibit much improved water solubility. 
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                   Figure 14. New design of next generation SSRIs based on analogue 69f 
 
Synthesis of N-benzyl-1-methyl-4-aryl-4-methylamine Derivatives (71) 
The synthesis of a N-benzyl piperidine analogues was achieved from piperidine nitriles as 
shown in Scheme 20. The first reduction step used Raney Ni in a saturated NH3/methanol 
solution in a hydrogen atmosphere (50 psi) and afford the primary amine 70 in 90% yield. The 
subsequent reductive amination gave the N-alkylated secondary amines 71 in 65-70% yields. 
The target compounds were converted in the oxalate salts and submitted for in vitro testing at 
dopamine transporter, serotonin transporter and norepinephrine transporter. The results of these 
bioassay studies will be reported elsewhere. 
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Scheme 20 
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CONCLUSIONS 
 
In conclusion, an efficient synthesis for derivatives of meperidine was developed to 
obtain a variety of meperidine derivatives as ligands for the serotonin transporter. This synthesis 
allowed for large-scale (gram) quantities of potent aryl-substituted derivatives of meperidine to 
be synthesized, as well as allow the facile incorporation of various substitutions and 
transformations on the meperidine system in order to future explore the structure-activity 
relationships at the serotonin transporter. The synthesis also minimized the use of toxic reagents 
and intermediates to provide a safe procedure to prepare the target compounds. 
From the in vitro binding affinity studies, the substituted aryl ring generally improved the 
serotonin transporter binding potency and selectivity.  Only compound 21h, bearing 4-methyl 
group as an electron-donating substituent, exhibited diminished potency relative to meperidine. 
For the analogues containing an electron-withdrawing substituent, the serotonin transporter 
binding affinity improved with larger substituents, such as 4-I-phenyl (21c), 3,4-Cl2-phenyl (21e), 
2-naphthyl (21f), and 4-biphenyl (21g) analogues. Also the µ-opioid receptor binding affinity 
was dramatically diminished by larger substituents. All these ring systems indicate a 
hydrophobic pocket at the serotonin transporter that can hold an aromatic ring system like the 4-
iodophenyl or biphenyl rings.  
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 Substituted benzyl esters exhibit higher potency and selectivity than the corresponding 
alkyl esters. The high affinity of these benzyl esters indicates that a second ring system is quite 
important for serotonin transporter recognition. Among the benzyl ester congeners, a substituted 
benzyl ring with a 3,4-Cl2 (67l), 4-NO2 (67m), 4-OCH3 (67n) group exhibited the highest 
potency and  selectivity in this series. 
The N-substitution of piperidine analogues decrease both the binding affinity at the 
serotonin transporter and the dopamine transporter. Substituents larger than a methyl group 
decreased the potency.  Presumably, the steric hindrance around the nitrogen atom blocks the 
nitrogen terminal for dopamine transporter and serotonin transporter recognition. Alternatively, 
N-demethylated meperidine analogues (69) generally exhibited improved serotonin transporter 
affinity and selectivity.  Compound 69f, the methoxylbenzyl-4-iodophenyl piperidine ester 
analogue, showed the highest selectivity and potency of the compounds prepared in this study 
with sub-nanomolar binding affinity (Ki = 0.6 nM) and selectivity at the serotonin transporter 
greater than 4500 times that of the dopamine transporter and the norepinephine transporter. This 
compound 69f will be advanced to in vivo bioassays and animal behavioral tests. 
Based upon the structure-activity studies, the pharmacophore of the meperidine 
analogues can be summarized in Figure 15. The substituted phenyl ring at 4-position is required 
for SERT binding recognition. Here, lipophilic groups are favored with the 4-iodo substiution 
preferred. The second aryl ring system of the benzyl esters is also crucial for high binding 
potency. Substitution on this aryl ring is favored by the electron-rich 4-methoxy group. Finally a 
secondary amine terminal leads to improved serotonin transporter selectivity.  
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                     Figure 12.  Meperidine analogue pharmacophore for SERT Binding. 
A series of N-benzyl piperidine analogues were synthesized as the next generation of 
SSRIs, based upon the ester analogues. These amine congeners are expected to maintain the high 
potency and selectivity with lower molecular weight, better bioavailability and extended half-life 
relative to ester analogues. The results of these bioassay studies are still undergoing and the 
binding data will be reported elsewhere. 
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EXPERIMENTAL SECTION 
 
All chemicals were purchased from Aldrich Chemical Co., Milwaukee, WI. unless 
otherwise noted. Anhydrous THF, CH2Cl2 and CH3OH were purchased from Mallinkrodt Baker. 
Toluene and Et2O (Drisolv®, EMD Chemicals) were purchased from VWR International. 
Chromatography refers to flash column chromatography on silica gel (Sorbent Technologies 
Silica Gel 60Å, 230-400 mesh, 32-63 µm Standrard Grade). Petroleum ether refers to pentanes 
with a boiling point range of 30-60 °C. Reported melting points are uncorrected and were 
determined using a Hoover Mel-Temp apparatus. NMR spectra were recorded on a Varian-
Gemini 400 MHz spectrometer. Chemical shifts are reported as δ values with tetramethylsilane 
(TMS), employed as the internal standard. Elemental analyses were obtained from Atlantic 
Microlabs, Inc. Norcross, GA. 
 
General Procedure A-1. Preparation of Hydrochloride Salts. 
Some of the compounds were converted into the hydrochloride salts for biological testing, as 
well as for storage and handling purposes. The base (50-100 mg) was dissolved in a minimum 
amount of diethyl ether (1-2 mL) and added to a saturated ethereal solution (10 mL) of 
anhydrous hydrogen chloride. The hydrochloride salts crystallized and were washed with Et2O (3 
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x 2 mL) and purified by trituration with Et2O and ethyl acetate. Fractional moles of water could 
not be prevented, despite vigorous drying (110 °C, 1h) under vacuum (0.01 mm Hg). All 
compounds were homogeneous on thin-layer chromatography (CHCl3/CH3OH/NH4OH, 90:9:1). 
 
General Procedure A-2. Preparation of Oxalic Acid Salts. 
Some of the final compounds were converted into the oxalic acid salts for biological testing, as 
well as for storage and handling purposes. The base (50-100 mg) was dissolved in a minimum 
amount of anhydrous THF (1-2 mL) and added to a saturated THF solution (10mL) of anhydrous 
oxalic acid. The salts crystallized and were washed with anhydrous THF (1 x 2 mL) and then 
washed with Et2O (3 x 2 mL) and purified by trituration with Et2O and ethyl acetate. Fractional 
moles of water could not be prevented, despite vigorous drying (110 °C, 1h) under vacuum (0.01 
mm Hg). All compounds were homogeneous by thin-layer chromatography (CHCl3/CH3OH 
/NH4OH, 90:9:1). 
 
2,2'-(Tosylazanediyl)bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate) (57). 151 
 
TsCl (33.3 mmol) in dry toluene (30 mL) was added to a stirred suspension of diethanolamine 
(9.51 mmol), Et3N (4.0 mmol) and Me3N•HCl (0.2 mmol) in toluene (10 mL) at 0-5 °C, and the 
mixture was stirred overnight. Water (20 mL) was added to the mixture, which was extracted 
with EtOAc (3 x 25 mL). The organic layers were combined and washed with brine, dried 
(Na2SO4) and concentrated under reduced pressure. The residue was purified by silica-gel 
column chromatograph (SiO2, hexane: EtOAc, 1:1) to give 57 as white solid (4.7 g, 91% 
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yield).1H NMR (CDCl3) δ 7.77-7.75 (d, J = 8.4 Hz, 3H), 7.63-7.61 (d, J = 8.4 Hz, 2H), 7.37-7.35 
(d, J = 8.0 Hz, 4H), 7.31-7.29 (d, J = 8.0 Hz, 3H), 4.11 (t, J = 8Hz, 4H), 3.38 (t, J = 6 Hz, 4H), 
2.46 (s, 6H), 2.43 (s, 3H). 
 
 
Synthesis of meperidine using Hartwig-Buchward method (62). 
 
The procedure was carried out in glove box under a dry Argon atmosphere. A solution of the 
ester 61 (173 mg, 1.1 mmol) in toluene (2 mL) was added to a vial containing 1.3 equiv of 
LiNCy2 (250 mg, 1.3 mmol). The solution was stirred for 10 min before it was transferred to a 
screw-capped vial containing a catalytic amount of Pd2(dba)3 (1.15 mg, 0.002 mmol)and the aryl 
halide 60 (225.9 mg, 1.0 mmol). Finally, P(t-Bu)3 (0.002 mmol, 0.5 µl) was added from a 0.5 M 
toluene stock solution. The vial was fitted with a PFTE septum and removed from the glove box. 
The reaction mixture was stirred at room temperature for 24 h. The target product methyl 1-
methyl-4-phenyl-4-carboxymethylpiperidine (62) was observed by GC-MS with low yields (< 
10%), m/z: found [ESI]: [MH+] 301.55, C14H17Cl2NO2 requires [MH+] 302.06. 
 
(4-Iodophenyl) Acetonitrile (29c).152  
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A mixture of KCN (2.7 g, 41 mmol) and deionized water (4.0 mL) was heated in an oil bath to 
dissolve the KCN. A solution of the 4-iodobenzyl bromide (9.8 g, 33 mmol) in MeOH (190 mL) 
was added to the reaction flask via addition funnel and allowed to stir at reflux for 4 h. The 
reaction mixture was allowed to cool to room temperature. The salts were filtered, and the filtrate 
was partially concentrated under reduced pressure. The resulting residue was purified by bulb-to-
bulb distillation. The impurities were collected from 80-100 °C and the product was collected 
from 100-120 °C. This compound was obtained as a white solid (4.8 g, 60% yield). mp 55-56 °C 
(lit.: mp 56-57 °C). 1H NMR (CDCl3) δ 7.71 (d, J= 8.4 Hz, 2H), 7.09 (d, J = 8.4Hz, 2H), 3.70 (s, 
2H). 13C NMR (CDCl3) δ 138.1, 129.7, 129.5, 117.2, 93.5, 23.2. 
 
General Procedure B. Dialkylation of 2-Aryl Acetonitriles 29a-h.121   
To a 100 mL round bottom flask fitted with a condenser, containing 2-aryl acetonitrile 29 (5.4 
mmol) and bromoacetaldehyde dimethyl acetal (13 mmol) in anhydrous toluene (7 mL) under an 
atmosphere of nitrogen, a suspension of 50% NaNH2 (50% by wt in toluene,1 equiv.) was added 
in portions. The reaction was allowed to stir at 70 °C to reflux for 15 min before the next portion 
of NaNH2 was added. This was repeated until the mono-substituted product was no longer 
visible using thin layer chromatograph (Et2O/ hexanes, 1:1). The reaction mixture was cooled to 
room temperature and quenched with deionized water. The aqueous layer was extracted with 
ether (4 x 25 mL). The combined organic fractions were dried (Na2SO4) and filtered. The solvent 
was removed under vacuum and the residue was purified by silica-gel column chromatography 
using a gradient of 25% Et2O/hexanes to 50% Et2O/hexanes to afford products 55a-h. 
 
2-(4-Fluorophenyl)-2-(2,2-dimethoxy-ethyl)-4,4-dimethoxy-butyronitrile (55a). 
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This compound was obtained from General Procedure B, as an orange solid (12 g, 66% yield). 
1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.44 (m, 2H), 7.10 (m, 2H), 4.27 (dd, J = 4.8, 
4.2 Hz, 2H), 3.23 (s, 6H), 3.17 (s, 6H), 2.40 (dd, J = 14.2, 6.6 Hz, 2H), 2.14 (dd, J = 4.0, 14.4 Hz, 
2H), 13C (101 MHz, CDCl3) δ 133.6, 127.7, 121.1, 115.7, 101.9, 53.6, 53.1, 43.7, 41.4. 
 
2-(4-Chlorophenyl)-2-(2,2-dimethoxy-ethyl)-4,4-dimethoxy-butyronitrile (55b). 
 
This compound was obtained from General Procedure B, as an orange solid (14 g, 66% yield). 
1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.42-7.40 (m, 3H), 4.27 (m, 2H), 3.32 (s, 
6H), 3.17 (s, 6H), 2.40 (dd, J = 6.8, 14.4 Hz, 2H), 2.13 (dd, J = 4.0, 14.4 Hz, 2H), 13C (101 MHz, 
CDCl3) δ 136.4, 133.7, 128.9, 127.4, 120.8, 101.9, 53.5, 53.1, 43.4, 41.5,     Anal.  Calcd. for  
C16H22NO4Cl: C, 58.62; H, 6.76; N, 4.27. Found: C, 58.70; H, 6.75; N, 4.19. 
 
2-(2,2-Dimethoxyethyl)-2-(4-iodophenyl)-4,4-dimethoxy-butyronitrile (55c). 
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The compound was obtained from General Procedure B, as an orange solid (6.9 g, 64% yield). 
mp 73-75 oC. 1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.8 Hz, 2H), 
7.22(d, J = 8.4 Hz, 2H), 4.27 (m, J = 4.0 Hz, 2H), 3.32 (s, 6H), 3.17 (s, 6H), 2,40 (dd, J = 7.2, 
14.4 Hz, 2H), 2.13 (dd, J = 4.4, 14.6 Hz, 2H), 13C (101 MHz, CDCl3) δ 137.8, 137.6, 127.8, 
120.7, 101.7, 93.3, 53.5, 53.1, 43.2, 41.3, Anal.  Calcd. for C16H22NO4I: C, 45.84; H, 5.29; N, 
3.34. Found: C, 46.11; H, 5.24; N, 3.33.  
 
2-(4-Bromophenyl)-2-(2,2-dimethoxy-ethyl)-4,4-dimethoxy-butyronitrile (55d). 
 
This compound was obtained from General Procedure B, as an orange solid (14 g, 66% yield). 
1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.8 Hz, 2H), 7.35 (d, J = 8.4 Hz, 
2H), 4.27 (m, 2H), 3.32 (s, 6H), 3.17 (s, 6H), 2,40 (dd, J = 6.4, 14.4 Hz, 2H), 2.13 (dd, J  = 4.0, 
14.4 Hz, 2H), 13C (101 MHz, CDCl3) δ 136.4, 133.7, 128.9, 127.4, 120.8, 101.9, 53.5, 53.1, 43.4, 
41.5, Anal.  Calcd. for C16H22NO4CI: C, 58.62; H, 6.76; N, 4.27. Found: C, 58.70; H, 6.75; N, 
4.19. 
 
2-(3,4-Dichlorophenyl)-2-(2,2-dimethoxyethyl)-4,4-dimethoxybutyronitrile (55e). 
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This compound was obtained from General Procedure B, as orange oil (7.9g, 81% yield). 1H 
NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J =2.4 Hz, 1H), 7.49 (d, J =8.4 Hz, 1H), 
7.31 (dd, J = 2.4, 8.4 Hz, 1H), 4.30 (m, J =4.4 Hz, 2H), 3.33 (s, 6H), 3.19 (s, 6H), 2,40 (dd, J = 
6.4, 14.4 Hz, 2H), 2.13 (dd, J = 4.4, 14.4 Hz, 2H), 13C (101 MHz, CDCl3) δ 137.8, 138.3, 133.0, 
132.1, 130.6, 128.1, 125.4, 120.4, 101.8, 53.6, 53.3, 43.3, 41.5.  Anal.  Calcd. for C16H21NO4Cl2: 
C, 53.05; H, 5.84; N, 3.87.  Found: C, 52.87; H, 5.77; N, 3.77.  
 
2-(2,2-Dimethoxyethyl)-4,4-dimethoxy-2-naphthalen-2-yl-butyronitrile (55f). 
 
This compound was obtained from General Procedure B, as orange oil (7.9 g, 76% yield).  1H 
NMR (free base): 1H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.87 (m, 3H), 7.52 (m, 3H), 4.28 
(dd, J = 4.0, 7.0 Hz, 2H), 3.31 (s,6H), 3.13 (s,6H), 2.50 (dd, J = 7.2, 14.2 Hz, 2H), 2.26 (dd, J = 
4.0, 14.6 Hz, 2H). 13C (101 MHz, CDCl3) δ 135.0, 133.1, 132.6, 128.9, 128.3, 127.5, 126.7, 
126.6, 125.6, 122.9, 121.3, 102.1, 53.7, 53.2, 43.5, 42.1.  Anal.  Calcd. for C20H25NO4: C, 69.95; 
H, 7.34; N, 4.08.  Found: C, 69.75; H, 7.22; N, 4.03. 
2-Biphenyl-4-yl-2-(2,2-dimethoxyethyl)-4,4-dimethoxy-butyronitrile (55g).  
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This compound was obtained from General Procedure B, as a yellow solid (9.4 g, 82% yield). 
mp 50-52oC. 1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.65 – 7.60 (m, 4H), 7.55 (m, 
2H), 7.44 (m, 2H), 7.35 (m, 1H), 4.33 (q, J = 4.0 Hz, 2H), 3.34 (s, 6H), 3.18 (s, 6H), 2,46 (dd, J 
= 6.8, 14.4 Hz, 2H), 2.21 (dd, J = 4.0, 14.4 Hz, 2H), 13C (101 MHz, CDCl3) δ 140.5, 139.7, 
136.7, 128.7, 127.5, 127.2, 126.8, 126.2, 121.1, 101.9, 53.4, 52.9, 43.4, 41.5, 13.9.  Anal.  Calcd. 
for C22H27NO4: C, 71.52; H, 7.37; N, 3.79.   Found: C, 71.62; H, 7.38; N, 3.80.  
 
General Procedure C. Reductive Amination of Diacetal Nitriles 55a-h.121 
To a three neck 100 mL round-bottom flask containing 3 N HCl (160 mL) at 50 °C was added 
the diacetal 6 (10 mmol) and the mixture was allowed to stir overnight. The acid mixture was 
allowed to cool down to room temperature and then extracted with EtO2 (300 mL). The ethereal 
layer was washed with saturated NaHCO3 (150 mL) and dried (Na2SO4). The Et2O was removed 
under reduced pressure. The resulting residue was dissolved in dry methanol (52 mL) and then 
the methylamine hydrochloride (25 mmol) was added, followed by the addition of NaBH3CN 
(9.4 mmol), and the mixture was allowed to stir for 48 h under an atmosphere of nitrogen. The 
methanol was removed under reduced pressure and the residue was treated with saturated 
NaHCO3  solution (160 mL) and the mixture extracted with Et2O (3 x 100mL). The combined 
organic fractions were dried (Na2SO4) and the solvent was removed under reduced pressure. The 
residue was purified by chromatography (CHCl3/CH3OH, 39:1) to afford 20a-h, respectively. 
 
4-(4-Fluorophenyl)-1-methyl-piperidine-4-carbonitrile (20b). 
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This compound was obtained from General Procedure C, as an orange solid (2.1 g, 30% yield). 
1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.47 (m, 2H), 7.09 (m, 2H), 2.96 (m, 2H), 
2.45 (m, 2H), 2.39(s, 3H), 2.09 (m, 4H).  13C (101 MHz, CDCl3) δ 162.2, 135.9, 127.3, 121.7, 
115.8, 52.6, 45.9, 41.6, 36.7.   
 
4-(4-Chlorophenyl)-1-methyl-piperidine-4-carbonitrile (20b). 
 
This compound was obtained from General Procedure C, as an orange solid (2.1 g, 30% yield). 
1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J =7.6 Hz, 2H), 7.37 (d, J = 9.2 Hz, 
2H), 2.96 (m, 2H), 2.48 (m, 2H), 2.38(s, 3H), 2.09 (m, 4H).  13C (101 MHz, CDCl3) δ 138.6, 
133.9, 129.1, 126.9, 121.4, 52.5, 45.9, 41.7, 36.4.   
 
4-(4-Iodophenyl)-1-methyl-piperidine-4-carbonitrile (20c). 
 
This compound was obtained from General Procedure C, as a yellow oil (1.9 g, 30% yield). 1H 
NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 8.4 Hz, 
78 
 
2H), 2.97 (d, J = 14.8 Hz, 2H), 2.48 (m, 2H), 2.39 (s, 3H), 2.09 (m, 4H).  13C (101 MHz, CDCl3) 
δ 139.8, 138.1, 127.5, 121.4, 93.7, 52.6, 46.0, 42.0, 36.4. 
 
4-(4-Bromophenyl)-1-methyl-piperidine-4-carbonitrile (20d). 
 
This compound was obtained from General Procedure C, as an orange solid (2.1 g, 30% yield). 
1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.55-7.54 (d, J = 8.4 Hz, 2H), 7.39-7.37 (d, J 
= 8.8 Hz, 2H), 3.04-3.01 (d, J = 6.0 Hz, 2H), 2.55 (m, 2H), 2.43(s, 3H), 2.19-2.09 (m, 4H).  13C 
(101 MHz, CDCl3) δ 138.6, 133.9, 129.1, 126.9, 121.4, 52.5, 45.9, 41.7, 36.4.   
 
4-(3,4-Dichlorophenyl)-1-mehtyl-piperidine-4-carbonitrile (20e).  
 
This compound was obtained from General Procedure C, as an orange oil (2.2 g, 39%). 1H NMR 
(free base): 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 2.0 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 7.31 
(dd, J = 2.4, 8.4 Hz, 1H), 2.95 (m, 2H), 2.46 (m, 2H), 2.07 (m, 4H), 13C (101 MHz, CDCl3) δ 
140.2, 133.2, 132.4, 130.9, 125.0, 121.0, 52.4, 45.8, 41.6, 36.3.  
 
 
79 
 
1-Methyl-4-naphthalen-2-yl-piperidine-4-carbonitrile (20f).  
 
This compound was obtained from General Procedure C, as an orange oil (2.3 g, 35% yield). 1H 
NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 1.6 Hz, 1H), 7.85 (m, 3H), 7.57 (dd, 
J = 2.0, 8.4 Hz, 1H), 7.50 (m, 2H), 2.99 (d, J = 12.0, 2H), 2.53 (m, 2H), 2.40 (s, 3H), 2.22 (m, 
4H). 13C (101 MHz, CDCl3) δ 137.3, 133.1, 132.7, 128.9, 128.1, 127.5, 126.6, 126.5, 124.6, 
123.3, 121.9, 52.7, 46.0, 42.3, 36.5.    
 
4-Biphenyl-4-yl-1-methyl-piperidine-4-carbonitrile (20g)  
 
This compound was obtained from General Procedure C, as an orange oil (2.2 g, 40%).  1H NMR 
(free base): 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.55 (m, 6H), 7.44 (m, 2H), 7.35 (m, 1H), 2.98 
(d, J = 12.6 Hz, 2.51 (m, 2H), 2.40 (s, 3H), 2.16 (m, 4H). 13C (101 MHz, CDCl3) δ 141.0, 140.1, 
139.1, 128.8, 127.6, 127.0, 126.0, 121.9, 52.7, 46.0, 41.9, 36.6.   
 
General Procedure D. Esterification of Nitriles 20a-h.121   
The nitrile 30 (5.2 mmol) in an aqueous solution of sulfuric acid (6.5 mL H2SO4:H2O,1:1) was 
heated in an oil bath at 120 °C for 1.5 h. The flask was then equipped with a Dean-Stark Trap 
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and excess alcohol was added. The water was azeotropically removed over 4.5 h and alcohol was 
added as needed. The reaction was heated to reflux overnight and then allowed to cool to room 
temperature. The alcohol was removed under reduced pressure. The flask was then cooled in an 
ice bath and the acid was neutralized to pH 10 with 1 N NaOH. The aqueous layer was extracted 
with Et2O (3 x 75 mL). The combined organic fractions were dried (Na2SO4) and the solvent was 
removed under reduced pressure. The residue was purified by chromatography (CHCl3/CH3OH, 
39:1) to afford esters 21a-h, respectively. 
 
4-Carboethoxy-(4-fluorophenyl)-1-methyl-piperidine (21a).     
 
This compound was obtained from General Procedure D as a white solid (1.0 g, 70% yield), and 
converted into a hydrochloride salt (General Procedure A-1), which was obtained as a white 
solid, mp 137-138 ºC. 1H  NMR (free base): δ 7.36 (m, 4H), 7.00 (m,2H), 4.12 (q, J = 6.8 Hz, 
2H), 2.78 (br s,  2H), 2.57 (d, J = 12.8 Hz, 2H), 2.26 (s, 3H), 2.13 (t, J = 11.2 Hz, 2H), 1.94 (m,  
2H), 1.18 (t, J = 7.2 Hz, 3H), 13C NMR (free base): δ 174.1, 161.7, 138.7, 127.5, 115.3, 60.8,  
53.4, 48.1, 46.2, 34.0, 14.0.   
4-Carboethoxy-(4-chlorophenyl)-1-methyl-piperidine (21b).     
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This compound was obtained from General Procedure D as a white solid (1.1 g, 70% yield), and 
converted into a hydrochloride salt (General Procedure A-1), which was obtained as a white 
solid, mp 168-169 ºC. 1H  NMR (free base): δ 7.31 (m, 4H), 4.12 (q, J = 6.8 Hz, 2H), 2.77 (br s,  
2H), 2.56 (d, J = 12.8 Hz, 2H), 2.27 (s, 3H), 2.13 (t, J = 11.2 Hz, 2H), 1.93 (t, J = 10.4 Hz, 2H), 
1.18 (t, J = 7.2 Hz, 3H), 13C NMR (free base): δ 174.0, 141.5, 132.9, 128.6, 127.3, 60.9, 53.4, 
48.3, 46.2, 33.6, 14.0.   
 
4-Carboethoxy-(4-iodophenyl)-1-methyl-piperidine (21c).    
 
This compound was obtained from General Procedure D as a white solid (1.1 g, 68% yield), and 
converted into a hydrochloride salt (General Procedure A-1), which was obtained as a white 
solid, mp 247-249 ºC. 1H  NMR (free base): δ 7.65 (d, J = 8.8 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 
4.12 (m, J = 7.2 Hz, 2H), 2.78 (d, J = 8.4 Hz, 2H), 2.54 (d, J = 13.2 Hz, 2H), 2.27 (s, 3H), 2.14 (t, 
J = 10.8 Hz, 2H), 1.94 (t, J = 10.4 Hz, 2H), 1.18 (t, J = 7.6 Hz, 3H), 13C NMR (free base): δ 
173.7, 137.5, 127.8, 92,7, 60.9, 53.2, 48.3, 46.1. 33.6, 14.0.  Anal.  Calcd. for C15H20NO2I·HCl: 
C, 43.98; H, 5.17; N, 3.42.  Found: C, 44.10; H, 5.23; N, 3.43. 
 
4-(4-Bromophenyl)-4-carboethoxy-1-methyl-piperidine (21d).     
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This compound was obtained from General Procedure D as a white solid (1.1 g, 80% yield), and 
converted into a hydrochloride salt (General Procedure A-1), which was obtained as a white 
solid, mp 247-249 ºC. 1H  NMR (free base): δ 7.47 (d, J = 8.8 Hz, 2H), 7.26 (d, J = 8.8 Hz, 2H), 
4.12 (q, J = 7.2 Hz, 2H), 2.78 (br s,  2H), 2.54 (d, J = 12.4 Hz, 2H), 2.26 (s, 3H), 2.13 (t, J = 11.2 
Hz, 2H), 1.93 (t, J = 11.2 Hz, 2H), 1.18 (t, J = 7.2 Hz, 3H). 
 
4-Carboethoxy-(3,4-dichlorophenyl)-1-methyl-piperidine (21e).   
 
This compound was obtained from General Procedure D as an off-white solid (1.2 g, 70% yield), 
and converted into a hydrochloride salt (General Procedure A), which was obtained as a white 
solid, mp 195-196 ºC. 1H  NMR (free base): δ 7.47 (d, J = 2.0 Hz, 1H), 7.40 (d, J = 8.8 Hz, 1H), 
7.23 (dd, J = 2.4, 8.4 Hz, 1H), 4.14 (m, J = 6.8 Hz, 2H), 2.80 (d, J = 8.4 Hz, 2H), 2.55 (d, J= 
12.8 Hz, 2H), 2.28 (s, 3H), 2.16 (t, J = 11.6 Hz, 2H), 1.94 (m, J = 11.2 Hz, 2H), 1.20 (t, J = 6.8 
Hz, 3H). 13C NMR (free base): δ 173.4, 132.6, 131.2, 130.4, 128.2, 125.4, 61.2, 53.2, 48.2, 46.0, 
33.6, 14.0.   Anal.  Calcd. for C15H19NO2Cl2: HCl: C, 51.08; H, 5.72; N, 3.97.  Found: C, 51.23; 
H, 5.78; N, 4.00. 
 
4-Carboethoxy-1-methyl-4-naphthalen-2-yl-piperidine (21f).     
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This compound was obtained from General  Procedure D as an off-white solid (1.2 g, 32% yield) 
and converted into a hydrochloride salt (General Procedure A), which was obtained as a white 
solid, mp 191-193 ºC. 1H NMR (free base): δ 7.80 (m, 4H), 7.55 (dd, J = 2.0, 8.6 Hz, 1H), 7.44 
(m, 2H), 4.12 (m, J = 6.8 Hz, 2H), 2.83 (d, J = 9.2 Hz, 2H), 2.70 (d, J = 12.4 Hz, 2H), 2.28 (s, 
3H), 2.21 (t, J = 11.6 Hz, 2H), 2.10 (m, 2H), 1.16 (t, J = 6.8 Hz, 3H). 13C NMR (free base): δ 
174.3, 133.3, 132.3, 128.1, 128.0, 127.3, 126.0, 125.9, 124.6, 124.0, 60.8, 53.5, 48.7, 46.2, 33.9, 
14.0.  Anal.  Calcd. for C19H23NO2·HCl: C, 68.36; H, 7.25; N, 4.20. Found: C, 68.27; H, 7.30; N, 
4.14. 
 
4-Biphenyl-4-carboethoxy-1-methyl-piperidine (21g).   
 
The compound was obtained from General Procedure D as a yellow solid (1.1 g, 80% yield) and 
converted into a hydrochloride salt (General Procedure A), which was obtained as a white solid, 
mp 196-198 ºC. 1H  NMR (free base): δ 7.54  – 7.28 (m, 9H), 4.10 (q, J = 6.8 Hz, 2H), 2.78 (d, J 
= 9.2 Hz, 2H), 2.61 (d, J = 12.8 Hz, 2H), 2.24(s, 3H), 2.15 (t, J = 11.2 Hz, 2H), 2.01 (t, J = 11.2 
Hz, 2H), 1.14 (t, J = 7.4 Hz, 3H). 13C NMR (free base): δ 174.3, 140.5, 139.8, 128.7, 127.3, 
84 
 
127.2, 127.0, 126.2, 60.9, 53.5, 48.5, 46.3, 33.9, 14.0.   Anal.  Calcd. for C21H25NO2·  HCl·1/4H2O: 
C, 69.21; H, 7.73; N, 3.84; Found: C, 69.47; H, 7.25; N, 3.80.  
 
 
 General Procedure E. Transesterification of Ethyl Ester of 21e. 124 
A flask containing oven-dried molecular sieves (500 mg) was charged with ICy·HCl (10 mol %), 
potassium t-butoxide (9.5 mol %), and THF (1 mL). The ethyl ester (1.0 mmol) and alcohol (1.5 
mmol) were dissolved in THF (0.5 mL) and added to the reaction mixture via cannula addition. 
The reaction was allowed to stir at room temperature and was monitored by TLC (CHCl3:MeOH, 
19:1). The mixture was filtered and the solvent removed under reduced pressure. The residue 
was purified using column chromatography to afford compounds 67a-h. 
 
General Procedure F. Hydrolysis of   Nitriles 20c,e,f .152 
A solution of the nitrile (5.2 mmol) and 25 % (wt) NaOH (34 mL) in methanol (100 mL) was 
stirred at reflux overnight, then cool down to room temperature.  The mixture was reduced to 
half the volume under reduced pressure and extracted with Et2O (3 x 30 mL). The aqueous layer 
was cooled to 0 °C, then acidified to pH = 2 with 1M HCl solution and then extracted with ethyl 
acetate (3 x 75 mL). A white suspension was formed and white solid was filtered by vacuum 
filtration. The solid was recrystallized from H2O/MeOH (4/1, v/v) to afford product 67g-o as 
white crystals. 
General Procedure G. Esterification of Carboxylic Acids 43g-o. 153 
Thionyl chloride (20 mL)
 
was transferred to a 100 mL round-bottom flask fitted with a condenser 
and filled with carboxylic acid 43g-o (1.85 mmol). The mixture was heated to reflux overnight 
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with stirring under N2. Excess thionyl chloride was removed by distillation with absorption 
device (Sat.NaOH solution). A solution of alcohol (1.85 mmol) and Bu4NHSO4 (0.36 mmol) in 
CH2Cl2 (20 mL) was transferred to the residue. The mixtures were cool to -5 °C then 5% NaOH 
(3mL) was added. Stirring was continued at -5 °C for 1 h and then the mixture was allowed to 
warm room temperature. The reaction was monitored by TLC every 30 minutes until the starting 
material was consumed. The organic layer was separated, washed with water, dried (Na2SO4), 
filtered and concentrated under reduced pressure. Purification by column chromatography 
(MeOH/CHCl3 2.5:98) gave ester 67g-o as white solids.  
 
4-Bromobenzyl-4-(3, 4-dichlorophenyl)-1-methylpiperidine-4-carboxylate (67h). 
N
CH3
Cl Cl
O
O
Br
 
Compound was obtained from General Procedure G as a white solid (411 mg, 50% yield) and 
converted into the HCl salt (General Procedure A-1), to afford a white foam. 1H NMR (free base): 
1H NMR (400 MHz, CDCl3) δ 7.45 – 7.41 (m, 3H), 7.38-7.36 (d, J = 8.0 Hz, 1H), 7.18-7.15 (m, 
1H), 7.07 – 7.05 (d, J = 8.0 Hz, 1H), 5.04(s, 2H), 2.76-2.74 (d, J = 8.4 Hz, 2H), 2.55-2.52 (d, J = 
12.0 Hz, 2H), 2.24 (s, 3H), 2.13-2.07 (t, J = 12.0 Hz, 2H ), 1.94 (t, J = 10.0 Hz, 2H). Anal. Calcd. 
for C20H20BrCl2NO2·HCl·1/2H2O: C, 47.78; H, 4.41; N, 2.79. Found: C, 47.70; H, 4.47; N, 2.73. 
 
4-Iodobenzyl-4-(3, 4-dichlorophenyl)-1-methylpiperidine-4-carboxylate (67i). 
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Compound was obtained from General Procedure C as a white solid (450 mg, 50% yield) and 
converted into the HCl salt (General Procedure A-1) to afford white foam. 1H NMR (free base): 
1H NMR (400 MHz, CDCl3) δ 7.65 – 7.63 (m, 2H), 7.40-7.36 (m, 2H), 7.18-7.15 (m, 1H), 6.93 – 
6.91 (d, J = 8.0, 2H), 5.03(s, 2H), 2.76-2.74 (d, J = 8.8, 2H), 2.55-2.52 (d, J = 12.0, 2H), 2.24 (s, 
3H), 2.11 (t, J = 10.4, 2H ), 1.94 (t, J = 10.8, 2H). Anal. Calcd. for C20H20Cl2INO2·HCl·H2O: C, 
43.00; H, 4.15; N, 2.51. Found: C, 43.01; H, 4.02; N, 2.39. 
 
2-Naphthyl-4-(3, 4-dichlorophenyl)-1-methylpiperidine-4-carboxylate (67j). 
 
Compound was obtained from General Procedure C as a white solid (385 mg, 50% yield) and 
converted into the HCl salt (General Procedure A-1), to afford white foam. 1H NMR (free base): 
δ 7.84– 7.74 (m, 2H), 7.40-7.36 (m, 2H), 7.60 (s, 1H), 7.51-7.45(m,2H), 7.35-7.33 (d, J = 8.0 
Hz,1H) 7.27 (s,1H) 7.20-7.17 (dd, J = 2.0,2.0 Hz,1H), 5.27(s, 2H), 2.76-2.74 (d, J = 5.6 Hz, 2H), 
2.59-2.56 (d, J = 12.0 Hz, 2H), 2.23 (s, 3H), 2.14 (t, J = 10.8 Hz, 2H ), 1.95 (t, J = 10.8 Hz, 2H). 
Anal. Calcd. for C24H23Cl2NO2·HCl·1.5H2O: C, 58.61; H, 5.53; N, 2.85. Found: C, 58.37; H, 
5.50; N, 2.83. 
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4-Biphenyl-4-(3, 4-dichlorophenyl)-1-methylpiperidine-4-carboxylate (67k). 
 
Compound was obtained from General Procedure C as a white solid  (410 mg, 51% yield) and 
converted into the HCl salt (General Procedure A-1), to afford a white foam 1H NMR (free base): 
δ 7.59– 7.53 (m, 4H), 7.46-7.43 (dd, J = 6.8, 2.0 Hz, 3H), 7.38-7.36 (d, J = 8.8 Hz, 2H), 7.27-
7.25(d, J = 8.0 Hz, 2H), 7.21-7.18 (dd, J = 2.4, 6.4 Hz, 1H), 5.15(s, 2H), 2.78-2.76 (d, J = 8.0 Hz, 
2H), 2.59-2.56 (d, J = 12.8 Hz, 2H), 2.25 (s, 3H), 2.15 (t, J = 10.8 Hz, 2H ), 1.96 (t, J = 10.8 Hz, 
2H). Anal. Calcd. for C26H25Cl2NO2·HCl·H2O: C, 61.37; H, 5.55; N, 2.75. Found: C, 61.33; H, 
5.48;  N, 2.84.
 
 
 
3,4-Dichlorobenzyl 4-(3,4-dichlorophenyl)-1-methylpiperidine-4-carboxylate (67l). 
N
CH3
Cl
Cl
O
O
Cl
Cl
 
Compound was obtained from General Procedure G as an off-white solid (400 mg, 50% yield)    
and converted into the HCl salt (General Procedure A-1), which was obtained as a white solid, 
mp 182-183 °C. 1H NMR (free base):1H NMR (400 MHz, CDCl3) 7.40 (dd, J = 2.4, 8.4 Hz, 2H), 
7.36(s, 1H), 7.18 (dd, J = 2.0, 2.1 Hz, 2H), 7.00 (dd, J = 2.0, 2.0 Hz, 1H) 5.04 (s, 2H), 2.83 (s, 
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2H), 2.58-2.55 (d, J = 12.8 Hz, 2H), 2.30 (s, 3H), 2.20-2.18 (dt, J = 8.0 Hz, 2H), 2.06-2.03 (d, J 
= 10.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 173.4, 141.3, 135.9, 133.1, 132.7, 131.8, 130.8, 
130.0, 128.5, 127.3, 125.6, 65.5, 53.3, 48.6, 46.3, 33.7. Anal. Calcd. for C20H19NO2Cl4·HCl: C, 
49.67; H, 4.17; N, 2.90. Found: C, 49.44; H, 4.27; N, 2.84. 
 
4-Nitrobenzyl 4-(3,4-dichlorophenyl)-1-methylpiperidine-4-carboxylate (67m). 
 
Compound was obtained from General Procedure G as a yellow solid (410 mg, 47% yield) and 
converted into a HCl salt (General Procedure A-1), which was obtained as an orange solid, mp 
187-189 °C. 1H NMR (free base): 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 8.8 Hz, 2H), 7.40 
(dd, J = 2.4, 8.4 Hz, 2H), 7.29 (d, J = 8.8 Hz, 2H), 7.13 (dd, J = 2.4, 2.4 Hz, 1H), 5.17 (s, 2H), 
2.74 (s, 2H), 2.56-2.53 (d, J = 12.4 Hz, 2H), 2.24 (s, 3H), 2.15-2.10 (dt, J = 10.8 Hz, 2H), 2.00-
1.98 (d, J = 11.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 173.4, 147.9, 142.8, 135.5, 133.1, 
131.9, 130.8, 128.6, 125.6, 124.0, 65.7, 53.3, 48.6, 46.3, 33.7. Anal. Calcd. for 
C20H20N2O4Cl2·HCl·1/4H2O: C, 51.74; H, 4.67; N, 6.03. Found: C, 51.74; H, 4.75; N, 5.83. 
 
4-Methoxylbenzyl 4-(3,4-Dichlorophenyl)-1-methylpiperidine-4-carboxylate (67n). 
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Compound was obtained from General Procedure G as a white solid (410 mg, 51% yield) and 
converted into the HCl salt (General Procedure A-1), to afford a white foam 1H NMR (free base): 
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.3, 1H), 7.34 (dd, J = 8.4, 4.1 Hz, 1H), 7.20 – 7.16 
(m, 1H), 7.13 (dt, J = 17.3, 8.2 Hz, 2H), 6.91 – 6.77 (m, 2H), 5.04 (s, 2H), 3.80 (s, 3H), 2.75-
2.73 (d, J = 9.2 Hz, 2H), 2.54-2.51 (d, J = 12.6 Hz, 2H), 2.23 (s, 3H), 2.12-2.10 (m, 2H), 1.92 (d, 
J = 10.8 Hz, 2H).13C NMR (101 MHz, CDCl3) δ 173.6, 159.6, 132.9. 131.5, 130.6, 130.2, 128.5, 
127.8, 125.6, 118.74, 114.1, 67.1, 55.9, 55.5, 53.4, 48.6, 46.3, 33.9. Anal. Calcd. for 
C21H23Cl2NO3·HCl·H2O: C, 54.50; H, 5.66; N, 3.03. Found: C, 52.37; H, 5.60; N, 3.03. 
 
4-Trifluromethyl-(3,4-dichlorophenyl)-1-methylpiperidine-4-carboxylate (67o). 
 
Compound was obtained from General Procedure C as a white solid (400 mg, 48% yield) and 
converted into the oxalic salt (General Procedure A-2) to afford a white foam 1H NMR (free 
base): (400 MHz, CDCl3) δ 7.57 (d, J = 8.0 Hz, 2H), 7.39 (m, 2H), 7.29 (d, J = 8.4 Hz, 2H), 7.18 
(dd, J = 2.0 Hz 1H), 5.15 (s, 2H), 2.80 (s, 2H), 2.56 (d, J = 12.8 Hz, 2H), 2.28 (s, 3H), 2.17 (t, J 
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= 10.8 Hz 2H), 2.01(t, J = 10.8 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 173.4, 139.5, 135.4, 
133.1, 130.8, 128.5, 128.3, 125.8, 125.8, 125.7, 125.6, 66.3, 53.2, 48.5, 46.2, 33.6.  
 
 
3,4-Dichlorobenzyl 4-(4-iodophenyl)-1-methylpiperidine-4-carboxylate (68a). 
 
Compound was obtained from General Procedure G as a white solid (500 mg, 48% yield) and 
converted into the oxalic acid salt (General Procedure A-2), to afford a white solid form. 1H 
NMR (free base): 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.60 (m, 2H), 7.43 – 7.32 (m, 1H), 7.18 – 
7.03 (m, 3H), 6.95 (dt, J = 16.2, 8.1 Hz, 1H), 5.03 (s, 2H), 2.93 – 2.67 (m, 2H), 2.55 (d, J = 12.9 
Hz, 3H), 2.26 (m, 3H), 2.20 – 2.09 (m, 2H), 2.01 (d, J = 10.0 Hz, 2H).  
 
4-Nitrobenzyl 4-(4-iodophenyl)-1-methylpiperidine-4-carboxylate (68b). 
 
Compound was obtained from General Procedure G as a white solid (400 mg, 45% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford white foam. 1H NMR (free 
base):1H NMR (400 MHz, CDCl3) δ 8.19 – 8.07 (m, 2H), 7.69 – 7.58 (m, 2H), 7.33 – 7.19 (m, 
91 
 
2H), 7.17 – 7.02 (m, 2H), 5.22 – 5.09 (m, 2H), 2.75 (s, 2H), 2.58-2.55 (d, J = 12.0, 2H), 2.31 – 
2.20 (m, 3H), 2.19 – 2.06 (m, 2H), 2.01 (d, J = 11.0, 2H).13C NMR (101 MHz, CDCl3)   δ 173.7, 
137.9, 128.3, 123.9, 123.3, 118.5, 115.5, 93.2,  65.4, 53.4, 46.4, 36.4, 33.7.  
 
4-Methoxylbenzyl 4-(4-iodophenyl)-1-methylpiperidine-4-carboxylate (68c). 
N
CH3
I
O
O
OCH3
 
Compound was obtained from General Procedure G as a white solid  (440 mg, 50% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam 1H NMR (free 
base):1H NMR (400 MHz, CDCl3) δ 7.67 – 7.56 (m, 2H), 7.19 – 6.98 (m, 4H), 6.89 – 6.74 (m, 
2H), 5.08 – 4.97 (m, 2H), 3.85 – 3.75 (m, 3H), 2.73 (s, 2H), 2.55-2.53 (d, J = 12.8 Hz, 2H), 2.20 
(d, J = 19.7 Hz, 3H), 2.15 – 2.00 (m, 2H), 1.94 (d, J = 11.0 Hz, 2H).13C NMR (101 MHz, CDCl3) 
δ 173.9, 159.8, 137.8, 130.1, 128.2, 127.9, 114.0, 93.0, 66.8, 55.5, 53.4, 48.7, 46.3, 33.7.  
 
3,4-Dichlorobenzyl 4-(naphthalen-2-yl)-1-methylpiperidine-4-carboxylate (68d). 
 
Compound was obtained from General Procedure G as a white solid (380 mg, 48% yield) and 
converted into the oxalic salt(General Procedure A-2), to afford a white foam 1H NMR (free 
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base): 1H NMR (400 MHz, CDCl3) δ 7.91 – 7.70 (m, 4H), 7.55 – 7.43 (m, 2H), 7.29 – 7.19 (m, 
2H), 7.14 (d, J = 1.9 Hz, 0H), 7.00 – 6.86 (m, 1H), 5.03 (s, 2H), 2.81 (s, 2H), 2.72-2.70 (d, J = 
8.0 Hz, 2H), 2.43 – 2.31 (m, 4H), 2.29 (s, 3H), 2.00 (d, J = 17.5 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 174.1, 136.1, 133.5, 132.8, 132.7, 130.6, 129.8, 128.7, 128.4, 127.7, 127.2, 126.5, 
126.5, 125.1, 124.0,   65.7, 53.4, 48.9, 46.1, 33.6.  
 
4-Nitrobenzyl 4-(naphthalen-2-yl)-1-methylpiperidine-4-carboxylate (68e). 
 
Compound was obtained from General Procedure G as a white solid (360 mg, 48% yield)   and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 8.04 – 7.91 (m, 2H), 7.79 (m, 4H), 7.50 (m, 3H), 7.18 (d, J 
= 8.6 Hz, 2H), 5.15 (m, 2H), 2.85 – 2.72 (m, 4H), 2.30 (s, 3H), 2.27 – 2.24 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ 174.2, 147.7, 143.2, 133.5, 132.6, 128.6, 128.3, 128.3, 127.7, 126.6, 126.6, 
125.2, 124.1, 123.8, 65.3, 53.6, 49.2, 46.5, 33.9.  
 
4-Methoxylbenzyl 4-(naphthalen-2-yl)-1-methylpiperidine-4-carboxylate (68f). 
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Compound was obtained from General Procedure C as a white solid (350 mg, 50% yield)  and 
converted into the oxalic salt (General Procedure A-2) to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.80 – 7.74 (m, 4H), 7.52 – 7.49 (m, 1H), 7.46 – 7.44 (m, 
2H), 7.12 – 7.10 (d, J = 8.0 Hz,2H), 6.78 – 6.75 (m, 2H), 5.05 (s, , 2H), 3.75 (s, 3H), 2.80 (s, 2H), 
2.71– 2.68 (d, J = 12.0 Hz, 2H), 2.26 (s, 3H), 2.18 – 2.12 (m, 4H). 13C NMR (101 MHz, CDCl3) 
δ 174.20, 159.8, 133.5, 132.6, 130.2, 128.5, 128.4, 128.0, 127.6, 126.4, 126.3, 125.1, 124.1, 
114.0, 66.9, 55.5, 53.3, 48.9, 45.8, 33.4.  
 
General procedure H. N-Demethylation of Benzyl 4-Aryl-1-methyl-piperidine Analogues 
(67,68).124 
A solution of 65 (6.1 mmol), sodium bicarbonate (9.1 mmol) and 1-chloro-ethylchloroformate 
(52 mmol) in 1,2-dichloroethane (27 mL) was heated to reflux under an atmosphere of nitrogen 
for 48 h. The mixture was filtered to remove any solids and the solvent was removed under 
reduced pressure. Methanol (115 mL) was added and the mixture was heated to reflux for 3 h. 
The solvent was removed under reduced pressure. Chloroform was added, washed with 1.8 N 
NaOH (30 mL) and water (30 mL), and then dried (Na2SO4). The crude product was purified by 
column chromatography (SiO2, CHCl3/CH3OH, 12:1) to afford the normeperidine analogues 
69a-j. 
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3,4-Dichlrobenzyl 4-(3,4-dichlorophenyl) piperidine-4-carboxylate (69a). 
 
Compound was obtained from General Procedure H as a white solid  (173 mg, 70% yield) and 
converted into the oxalic salt(General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.40 (dd, J = 14.3, 8.3, 2H), 7.32 (d, J = 1.9 Hz, 1H), 7.17 – 
7.06 (m, 2H), 6.98 (dd, J = 8.2 Hz, 1.6, 1H), 5.06 (s, 2H), 3.44 (d, J = 12.8 Hz, 2H), 3.04 (t, J = 
11.7 Hz, 2H), 2.68 (d, J = 14.4 Hz, 2H), 2.42 – 2.21 (m, 2H).  13C NMR (101 MHz, CDCl3) δ 
171.9, 151.1, 139.9, 134.9, 132.9, 131.2, 130.9, 130.2, 128.0, 127.5, 125.1, 66.4, 55.9, 48.1, 41.9, 
34.6.  Anal.  Calcd. for C19H17Cl4NO2·C2H2O4·1/2H2O: C, 47.39; H, 3.79; N, 2.63. Found: C, 
47.60; H, 3.83; N, 2.74. 
 
 4-Nitrobenzyl 4-(3,4-dichlorophenyl) piperidine-4-carboxylate (69b). 
 
Compound was obtained from General Procedure H as a white solid (163 mg, 69% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 8.5 Hz, 2H), 7.45 – 7.36 (m, 2H), 7.32 (d, J = 
8.7 Hz, 2H), 7.24 – 7.15 (m, 1H), 5.19 (s, 2H), 3.07 (d, J = 12.7 Hz, 2H), 2.77 (t, J = 11.5 Hz, 
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2H), 2.54 (d, J = 13.1 Hz, 2H), 2.39 (s, 1H), 1.99 – 1.78 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
173.4, 147.9, 142.8, 142.8, 133.1, 131.8, 130.8, 128.6, 128.4, 125.5, 123.9, 65.7, 49.5, 43.9, 34.6. 
Anal. Calcd. for C19H18Cl2N2O4·C2H2O4: C, 50.52; H, 4.04; N,5 .61. Found: C, 50.60; H, 4.15; N, 
5.33. 
 
4-Methoxylbenzyl 4-(3,4-dichlorophenyl) piperidine-4-carboxylate (69c). 
 
Compound was obtained from General Procedure H as a white solid (160 mg, 71% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.29 (m, 2H), 7.11 (t, J = 10.2 Hz, 4H), 6.83 (d, J = 
8.5 Hz, 2H), 5.06 (s, 2H), 3.80 (s, 3H), 3.43 (s, 2H), 2.98 (s, 2H), 2.65 (d, J = 13.1 Hz, 2H), 2.29 
(s, 2H). 13C NMR (101 MHz, CDCl3) δ 173.6, 159.9, 143.2, 132.9, 131.5, 130.6, 130.2, 128.4, 
127.7, 125.5, 114.0, 67.1, 55.5, 49.4, 44.0, 34.6.  Anal. Calcd. for C20H21Cl2NO3·C2H2O4·0.1H2O:  
C, 54.36; H, 4.81; N, 2.88. Found: C, 54.70; H, 4.91; N, 2.87. 
 
3,4-Dichlorobenzyl 4-(4-iodophenyl) piperidine-4-carboxylate (69d). 
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Compound was obtained from General Procedure H as a white solid (196 mg, 70 % yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base):  1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.2 Hz, 1H), 7.13 (d, 
J = 1.8 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 6.96 (dd, J = 8.2, 1.8 Hz, 1H), 5.02 (s, 2H), 3.07 (s, 
2H), 2.79 (d, J = 6.9 HZ, 2H), 2.53 (s, 2H), 1.87 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 173.8,  
142.3, 138.0, 136.1, 132.9, 132.5, 131.1, 130.7, 129.8, 128.1, 127.2, 93.4, 65.3, 49.6, 43.94, 34.6. 
Anal. Calcd. for C19H18Cl2INO2·C2H2O4: C, 43.47; H, 3.47; N, 2.41. Found: C, 43.92; H, 3.59; N, 
2.39. 
 
4-Nitrobenzyl 4-(4-iodophenyl) piperidine-4-carboxylate (69e). 
 
Compound was obtained from General Procedure H as a white solid (186 mg, 72% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base):  1H NMR (400 MHz, CDCl3) δ 8.14 (d, J = 8.7 Hz, 2H), 7.66 (t, J = 5.5 Hz, 2H), 7.33 – 
7.22 (m, 2H), 7.11 (d, J = 8.6 Hz, 2H), 5.17 (s, 2H), 3.06 (d, J = 12.5 Hz, 2H), 2.77 (t, J = 11.6 
Hz, 2H), 2.54 (d, J = 12.6 Hz, 2H), 2.16 – 1.49 (m, 2H).  13C NMR (101 MHz, CDCl3) δ 173.9, 
143.1, 138.0, 128.4, 128.1, 123.9, 104.5, 93.2, 65.4, 49.7, 44.1, 34.6. Anal. Calcd. for 
C19H19IN2O4·C2H2O4: C, 45.34; H, 3.80; N, 5.04.  Found: C, 46.44; H, 4.15; N, 4.69. 
 
4-Methoxylbenzyl 4-(4-iodophenyl) piperidine-4-carboxylate (69f). 
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Compound was obtained from General Procedure H as a white solid (168mg, 73% yield)   and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.6 Hz, 2H), 7.11 (d, J = 8.6 Hz, 2H), 7.03 (d, J 
= 8.6 Hz, 2H), 6.82 (d, J = 8.7 Hz, 2H), 5.03 (s, 2H), 3.80 (s, 3H), 3.33 – 3.08 (m, 2H), 2.99 – 
2.70 (m, 2H), 2.72 – 2.43 (m, 2H), 2.28 – 1.95 (m, 2H).13C NMR (101 MHz, CDCl3) δ 173.3, 
159.9, 138.0, 137.7, 130.2, 129.9, 128.0, 127.9, 127.5, 114.2, 114.0, 93.4, 67.3, 55.5, 49.8, 33.7. 
Anal. Calcd. for C20H22INO3·C2H2O4: C, 48.81;  H, 4.47; N, 2.59. Found: C, 49.50; H, 4.71; N, 
2.52. 
 
3,4-Dichlorobenzyl 4-(naphthalen-2-yl) piperidine-4-carboxylate (69g). 
 
Compound was obtained from General Procedure H as a white solid  (180 mg, 71% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base):1H NMR (400 MHz, CDCl3) δ 7.88 – 7.74 (m, 4H), 7.54 – 7.41 (m, 3H), 7.25 – 7.17 (m, 
1H), 7.17 – 7.06 (m, 1H), 6.98 – 6.85 (m, 1H), 5.09 – 4.94 (m, 2H), 3.10 (t, J = 22.6 Hz, 2H), 
2.87 (dd, J = 25.4, 14.1 Hz, 3H), 2.68 (d, J = 13.2 Hz, 2H), 2.16 – 1.93 (m, 2H). 13C NMR (101 
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MHz, CDCl3) δ 174.2, 139.7, 136.2, 133.5, 132.8, 132.7, 132.4, 130.6, 129.8, 128.7, 128.4, 
127.7, 127.2, 126.6, 126.55, 126.5, 125.1, 123.9, 65.2,  49.9, 44.1, 34.6. Anal. Calcd. for 
C23H21Cl2NO2·C2H2O4: C, 59.53; H, 4.60; N, 2,78. Found: C, 59.53; H, 5.02; N, 2.60. 
 
4-Nitrobenzyl 4-(naphthalen-2-yl) piperidine-4-carboxylate (69h). 
N
H
O
O
NO2
 
Compound was obtained from General Procedure H as a white solid (160 mg, 73% yield)   and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 8.01 – 7.92 (m, 2H), 7.85 – 7.77 (m, 2H), 7.76 – 7.71 (m, 
1H), 7.71 (s, 1H), 7.55 – 7.46 (m, 2H), 7.42 – 7.34 (m, 1H), 7.20 – 7.07 (m, 2H), 5.30 – 5.07 (m, 
2H), 3.54 – 3.36 (m, 2H), 3.16 (t, J = 11.1 Hz, 2H), 2.84 (t, J = 14.3 Hz, 2H), 2.52 (t, J = 10.9 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ 172.7, 147.9, 142.3, 133.4, 132.8, 129.2, 128.6, 128.4, 
128.3, 127.7, 127.1, 127.0, 125.2, 123.9, 123.2, 65.9, 48.6, 42.0, 30.5.  Anal. Calcd. for 
C23H22N2O4·C2H2O4·1/2H2O: C, 61.34;  H,5.15;  N,5.72. Found: C, 61.85; H, 5.04; N, 5.68. 
 
 4-Methoxylbenzyl 4-(Naphthalen-2-yl) piperidine-4-carboxylate (69i). 
99 
 
 
Compound was obtained from General Procedure H as a white solid (150 mg, 72% yield)  and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.66 (m, 4H), 7.54 – 7.40 (m, 3H), 7.17 – 7.05 (m, 
2H), 6.85 – 6.69 (m, 2H), 5.05 (s, 2H), 3.75 (s, 3H), 3.12-3.05 (m, 2H), 2.84 (s,  2H), 2,67 (s, 
2H), 2.03 (t, J =10.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 174.5, 159.8, 140.3, 133.5, 132.6, 
130.1, 128.5, 128.4, 128.1, 127.6, 126.4, 126.2, 124.9, 124.2, 114.0, 66.8, 55.4, 49.9, 34.8. Anal. 
Calcd. for C24H25NO3·C2H2O4·1/3H2O: C, 66.32; H, 5.91; N, 2.97. Found: C, 66.34; H, 5.95; N, 
2.93. 
 
4-Trifluromethylbenzyl 4-(3,4-dichlorophenyl) piperidine-4-carboxylate (69j). 
 
Compound was obtained from general method H as a white solid (180mg, 72% yield) and 
converted into the HCl salt (General Procedure A-1), to afford a white foam. 1H NMR (free base): 
1H NMR (400 MHz, CDCl3) δ 7.67 – 7.50 (m, 2H), 7.46 – 7.35 (m, 2H), 7.27 (t, J = 9.1 Hz, 2H), 
7.17 (td, J = 8.2, 2.4 Hz, 1H),5.04 (s, 2H), 3.22 – 2.93 (m, 2H), 2.89 – 2.66 (m, 2H), 2.53 (d, J = 
13.2 Hz, 2H), 2.35 – 2.14 (m, 1H), 1.99 – 1.72 (m, 2H).13C NMR (101 MHz, CDCl3) δ 173.5, 
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142.9, 139.6, 133.0, 131.7, 130.7, 128.4, 128.3, 125.8, 125.8, 125.7, 125.7, 125.5, 122.8, 66.2, 
49.5, 44.1, 43.9, 34.8, 34.8, 29.9. Anal. Calcd. for C20H18Cl2F3NO2·HCl·1/3H2O: C, 50.60; H, 
4.18; N, 2.95.  Found: C: 50.65; H, 4.27; N, 2.92 
 
General procedure I. Reduction of 4-(3,4 Dichlorobenzyl) Piperidine Nitrile  (20d).154 
In a pressure reaction bottle were placed nitrile 20d (1.73g, 6.3mmol), anhydrous methanol (40 
mL), and Raney Ni (1.97 g). Anhydrous NH3 was bubbled through the solution until saturated. 
The reaction bottle was sealed and fixed to Parr Hydrogenation apparatus. After shaking at room 
temperature overnight under an atmosphere of H2 (50 psi), the reaction mixture was filtered 
through a layer of celite and the filtrate was concentrated under reduced pressure to yield 70 
(1.53 g, 97%) as a white solid. The product was dried overnight under vacuum and used in 
subsequent reactions with no further purification. 
 
General Procedure J.  Reductive Amination of 4-(3,4-Dichlorobenzyl)-piperidines (70).155 
The amine 70 (0.82 mmol), benzaldehyde (0.82 mmol), NaBH3CN (51.4 mg, 0.818 mmol)  and 
glacial acetic acid (51.4 mg, 0.82mmol) were combined in a 100 mL round-bottom flask, with 
CH2Cl2 (30 mL) and mixture was allowed to stir overnight at room temperature.  The mixture 
was then treated with saturated Na2CO3 solution and extracted with CH2Cl2 (3 x 25 mL). The 
combined organic fractions were dried (Na2SO4) and the solvent was removed under reduced 
pressure. The residue was purified by chromatography (CHCl3/CH3OH, 9:1) to afford 71a-h, 
respectively. 
 
N-Benzyl-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine (71a). 
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Compound was obtained from General Procedure J as a white solid  (203 mg, 70% yield)  and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.38 (m, 2H), 7.30 – 7.26 (m, 2H), 7.25 – 7.22 (d, J 
= 8.8 Hz 1H), 7.16 – 7.13 (m, 3H), 3.64 (s, 2H), 2.64 (s, 2H), 2.48 (s, 2H), 2.20 (s, 3H), 2.16-
2.12 (d, J = 14.0 Hz, 4H), 1.94-1.88 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 140.6, 132.8, 
130.5, 130.2, 129.6, 128.5, 128.0, 127.1, 126.9, 54.1, 52.1, 46.4, 40.4, 33.9. Anal. Calcd. for 
C20H24Cl2N2·1.5C2H2O4·H2O: C, 53.50; H, 5.66; N, 5.42. Found: C, 53.54; H, 5.74; N, 5.13. 
 
N-(4-Methylbenzyl)-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine (71b). 
 
Compound was obtained from General Procedure J as a white solid  (200 mg, 70% yield)  and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.38 (m, 2H), 7.15 – 7.13 (m, 1H), 7.08 – 7.06 (d, J 
= 8.0 Hz, 2H), 7.02 – 7.00 (d, J = 8.0 Hz, 2H), 3.59 (s, 2H), 2.63 (s, 2H), 2.49 (s, 2H), 2.31 (s, 
3H), 2.20 (s, 3H), 2.15-2.11 (d, J = 15.2 Hz, 4H), 1.91 (dd, J = 16.3, 6.4 Hz, 2H). 13C NMR (101 
MHz, CDCl3) δ 137.5, 136.6, 132.7, 130.4, 130.2, 129.6, 129.2, 127.9, 126.9, 53.9, 52.1, 46.4, 
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40.4, 33.9, 21.3. Anal. Calcd. for C21H26Cl2N2·C2H2O4·2H2O: C, 54.87; H, 6.41; N, 5.56. Found: 
C, 54.51; H, 6.38; N, 4.45. 
 
N-(4-Trifloromethylbenzyl)-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine 
(71c). 
 
 
Compound was obtained from General Procedure J as a white solid  (258 mg, 72% yield)  and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.51 (d, J = 8.0 Hz, 2H ), 7.41 – 7.39 (m, 2H), 7.28 – 
7.26 (d, J = 8.0 Hz, 2H), 7.16 – 7.14 (d, J = 8.0 Hz, 2H), 3.68 (s, 2H), 2.62 (s, 2H), 2.48 (s, 2H), 
2.20 (s, 3H), 2.16-2.13 (d, J = 12.1 Hz, 4H), 1.91 (dd, J = 16.6, 6.6 Hz, 2H). 13C NMR (101 MHz, 
CDCl3) δ 144.7, 132.8, 130.5, 130.3, 129.6, 128.2, 126.9, 125.4, 125.4, 125.3, 53.6, 52.0, 46.4, 
40.5, 33.9. Anal. Calcd. for C21H23Cl2F3N2·C2H2O4·1.5H2O: C, 50.37; H, 5.15; N, 5.11. Found: 
C, 50.90; H, 5.10; N, 5.11. 
 
N-(4-Bromobenzyl)-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine (71d). 
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Compound was obtained from General Procedure J as a white solid  (247 mg, 70% yield)  and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.36 (m, 4H ), 7.15 – 7.12 (d, J = 8.5, 2.3 Hz, 1H), 
7.03 – 7.00 (d, J = 8.4 Hz, 2H), 3.57 (s, 2H), 2.60 (s, 2H), 2.48 (s, 2H), 2.20 (s, 3H), 2.15-2.11 (d, 
J = 14.3 Hz, 4H), 1.89 (dd, J = 16.4, 6.5 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 139.6, 132.8, 
131.5, 130.5, 130.3, 129.7, 129.6, 126.9, 120.8, 53.4, 52.0, 46.4, 40.4, 33.9. Anal. Calcd. for 
C21H23BrCl2N2·C2H2O4·H2O: C, 48.02; H, 4.95; N, 5.09. Found: C, 48.17; H, 5.02; N, 4.54. 
 
N-(3,4-Dichlorobenzyl)-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine 
(71e). 
 
 
Compound was obtained from General Procedure J as a white solid  (253mg, 72% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.36 (m, 2H ), 7.29 – 7.26 (m, 1H), 7.21-7.20 (d, J = 
2.0 Hz, 1H), 7.14-7.11 (dd, J = 6.0, 2.4 Hz, 1H), 6.96-6.93 (dd, J = 6.0, 2.4 Hz, 1H), 3.55 (s, 2H), 
2.58 (s, 2H), 2.45 (s, 2H), 2.17 (s, 3H), 2.13-2.09 (d, J = 14.0 Hz, 4H), 1.90-1.84 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 141.0, 132.8, 132.5, 130.8, 130.5, 130.4, 129.8, 129.6, 127.3, 126.9, 
52.8, 52.0, 46.4, 40.4, 33.8. Anal. Calcd. for C20H22Cl4N2·C2H2O4·H2O: C, 48.91; H, 4.85; N, 
5.19. Found: C, 49.05; H, 5.01; N, 4.55. 
 
 
104 
 
 
N-(4-Methoxylbenzyl)-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine (71f). 
 
Compound was obtained from General Procedure J as a white solid  (243 mg, 70% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.37 (m, 2H ), 7.14 – 7.12 (dd, J = 6.4, 2.0 Hz, 1H), 
7.05-7.03 (d, J = 8.0 Hz, 2H), 6.80-6.78 (d, J = 8.0 Hz, 2H), 3.78 (s, 3H), 3.55 (s, 2H), 2.62 (s, 
2H), 2.49 (s, 3H), 2.21 (s,3H), 2.15-2.11 (d, J = 14.0 Hz, 4H), 1.93-1.87 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 158.7, 132.7, 132.6, 130.4, 130.2, 129.5, 129.1, 126.9, 113.8, 55.5, 53.5, 52.0, 
46.3, 40.4, 33.8. Anal. Calcd. for C21H26Cl2N2O·C2H2O4·H2O: C, 55.09; H, 6.03; N, 5.59. Found: 
C, 55.24; H, 5.96; N, 5.56. 
 
N-(4-Nitrobenzyl)-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine (71g). 
 
Compound was obtained from General Procedure J as a white solid  (167 mg, 67% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 8.05 – 8.03 (d, J = 4.0 Hz, 2H), 7.36-7.34 (m,2H), 7.29 – 
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7.26 (m,2H), 7.14-7.11 (m,  1H), 3.68 (s, 3H), 2.59 (s, 2H), 2.43 (s, 2H), 2.15 (s,3H), 2.09 (m, 
4H), 1.88-1.83 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 148.5, 147.1, 132.8, 130.5, 130.3, 129.6, 
128.6, 126.9, 123.6, 53.3, 52.0, 46.4, 40.5, 33.8. Anal. Calcd. for C20H23Cl2N3O2·C2H2O4·H2O: C, 
51.17; H, 5.27; N, 8.14. Found: C, 51.14; H, 5.04; N, 7.69. 
 
N-(2-Naphthyl)-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine (71h). 
 
Compound was obtained from General Procedure J as a white solid  (258mg, 68% yield)and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.81-7.91 (m, 1H), 7.76-7.74 (d, J = 8.0, 2H), 7.54 (s, 1H), 
7.46 – 7.43 (m, 2H), 7.42 – 7.38 (m, 2H), 7.27-7.26 (m, 2H), 7.16-7.14 (dd, J = 8.5, 2.2, 1H), 
3.80 (s, 2H), 2.68 (s, 2H), 2.49 (s, 2H), 2.19 (s, 3H), 2.16-2.13 (m, 4H), 1.95-1.92 (m, 2H).13C 
NMR (101 MHz, CDCl3) δ 138.0, 133.5, 132.8, 132.7, 130.5, 130.3, 129.6, 128.2, 127.9, 127.0, 
126.4, 126.3, 126.2, 125.7, 54.2, 52.1, 46.4, 40.5, 34.0. Anal. Calcd. for 
C24H26Cl2N2·C2H2O4·1.75H2O: C, 58.38; H, 5.94; N, 5.24. Found: C, 58.38; H, 5.89; N, 4.59. 
 
N-(4-Biphenyl)-1-(4-(3,4-dichlorophenyl)-1-methylpiperidin-4-yl)methanamine (71i). 
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Compound was obtained from General Procedure J as a white solid (263mg, 70% yield) and 
converted into the oxalic salt (General Procedure A-2), to afford a white foam. 1H NMR (free 
base): 1H NMR (400 MHz, CDCl3) δ 7.61-7.59 (m, 2H), 7.53-7.51 (d, J = 8.0, 2H), 7.46 – 7.40 
(m, 4H), 7.36 – 7.32 (m, 1H), 7.23-7.21 (m, 2H), 7.19-7.17 (m, 1H), 3.69 (s, 2H), 2.69 (s, 2H), 
2.51 (s, 2H), 2.22 (s, 3H), 2.19-2.15 (m, 4H), 1.97-1.94 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
141.2, 140.0, 139.7, 132.8, 130.5, 130.2, 129.6, 129.0, 128.7, 128.4, 127.4, 127.3, 127.3, 126.9, 
53.8, 52.1, 46.4, 40.5, 34.0.Anal. Calcd. for C26H28Cl2N2·C2H2O4·2H2O: C, 59.47; H, 6.06; N, 
4.95. Found: C, 59.35; H, 5.95; N, 4.47. 
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Dr. Sari Izenwasser and coworkers at University of Miami, School of Medicine performed the 
in vitro binding assays for the dopamine, serotonin and norepinephrine transporters. 
 
[3H] WIN 35,428 Binding Assay. 
Male Sprague-Dawley rats (200-250 g,Taconic, Germantown,NY) were decapitated and 
their brains removed to an ice-cooled dish for dissection of the caudate-putamen.the tissue was 
homogenized in 30 volumes of ice-cold modified Krebs-HEPES buffer (15 mM HEPES, 127Mm 
NaCl, 5mM KCl,1.2 mM MgSO4,2.5 mM CaCl2, 1.3 mM NaH2PO4,10 mM glucose, pH adjusted 
to 7.4) using a Teflon/glass homogenizer and centrifuged at 20000g for 10 min at 4℃. The 
resulting pellet was then washed two more times by re-suspension in ice-cold buffer and 
centrifugation at 20000g for 10 min at 4℃. Fresh homogenates were used in all experiments. 
Binding assays were conducted in modified Krebs-HEPES buffer on ice, essentially as 
previously described. The total volume in each tube was 0.5 mL, and the final concentration of 
membrane after all additions was approximately 0.3% (w/v) corresponding to 150-300 g of 
protein/sample. Increasing concentrations of the drug being tested were added to triplicate 
samples of membrane suspension. Five minutes later, [3H] WIN 35,428 (final concentration 1.5 
nM) was added and the incubation was continued for 1h on ice. The incubation was terminated 
by the addition of 3 mL of ice-cold buffer and rapid filtration through Whatman/GF/B glass fiber 
filter paper (presoaked in 0.1 BSA in water to reduce nonspecific binding) using a Brandel Cell 
Harvester (Gaitherburg, MD). After filtration, the filters was washed with three additional 3 mL 
washes and transferred to scintillation vials. Absolute ethanol (0.5 mL) and Beckman Ready 
Value Scintillation Cocktail (2.75 mL) were added to the vials which were counted the next day 
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at an efficiency of about 36%. Under these assay conditions, an average experiment yielded 
approximately 6000 dpm total binding per sample and approximately 250 dpm nonspecific 
binding. Nonspecific binding was defined as binding in the presence of 100 µM cocaine. Ki 
values were derived from 14 point competition assays using increasing concentrations of 
unlabeled compounds (0.05 nM to 100 µM) against 1.5 nM [3H] WIN 35  428. Data were 
analyzed with Graphpad Prism software (San Diego, Califonia). 
 
[3H]Paroxetine Binding Assay. 
Brains from male Sprague-Dawley rats weighing 200-225 g (Taconic Labs) were 
removed, and midbrain was dissected and rapidly frozen. Membranes were prepared by 
homogenizing tissues in 20 volumes (w/v) of 50 mM Tris containing 120 mM NaCl and 5 mM 
KCl (pH 7.4 at 25 °C), using a Brinkman Polytron (setting 6 for 20 s) and centrifuged at 50,000g 
for 10 min at 4 °C. The resulting pellet was re-suspended in buffer, recentrifuged, and re-
suspended in buffer to a concentration of 15 mg/mL. Ligand binding experiments were 
conducted in assay tubes containing 4.0 mL buffer for 90 min at room temperature. Each tube 
contained 0.2 nM [3H]paroxetine (New England Nuclear, Boston MA)and 1.5 mg midbrain 
tissue (original wet weight). Nonspecific binding was determined using 1 µM citalopram. 
Incubations were terminated by rapid filtration through Whatman GF/B filters, presoaked in 0.05% 
polyethylenimine, using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, 
MD). The filters were washed twice with 5 mL cold buffer and transferred to scintillation vials. 
Beckman Ready Safe (3.0 mL) was added, and the vials were counted the next day using a 
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Beckman 6000 liquid scintillation counter (Beckman Coulter Instruments, Fullerton, CA). Data 
were analyzed by using GraphPad Prism software (San Diego, CA). 
 
[3H]Nisoxetine Binding Assay.  
Frontal cortex of male Sprague-Dawley rats was removed and frozen. Membranes were prepared 
by homogenizing tissues in 50 mM Tris (120 mM NaCl, 5 mM KCl; pH 7.4 at 25 °C) and 
centrifuging (50 000g for 10 min at 4 °C. The resulting pellet was then washed and centrifuged 
two more times. The final pellet was re-suspended to a concentration of 80 mg/mL (original wet 
weight). Assays were conducted in the above Tris buffer. Volume totaled 0.5 mL with tissue 
concentration of 8 mg/tube. [3H]Nisoxetine (specific activity 80 Ci/mmol; final concentrated 0.5 
nM, New England Nuclear, Boston, MA) was added and the incubation continued for 1 h on ice. 
Incubations were terminated by rapid filtration through Whatman GF/B filters, presoaked in 0.05% 
polyethylenimine (PEI). Nonspecific binding was defined using 1 M desipramine. For these 
assays, an initial screen was conducted to assess displacement of nisoxetine at a concentration of 
from 0.01 nM to 100 µM of the unknown compound. If there was greater than 50% displacement 
of nisoxetine, a Ki value was determined in subsequent studies.  
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